Prostaglandin EP4 receptor antagonist compounds
By developing new EP4 antagonist compounds, the problem of significant side effects of existing COX inhibitors in treating various diseases has been solved, enabling effective treatment and prevention of EP4 receptor-related diseases and providing a better risk-benefit ratio.
Patent Information
- Application Number
- CN202080071435.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2019-10-09
- Filing Date
- 2020-10-09
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2040-10-09
AI Technical Summary
In existing technologies, COX inhibitors have significant side effects and a disproportionate benefit-risk ratio when treating a variety of diseases. In particular, in cancer chemoprevention, more specific drugs are needed to neutralize PGE2 biology to reduce side effects and provide clinical benefits.
A series of new compounds have been developed as prostaglandin E2 receptor 4 (EP4) antagonists to specifically neutralize PGE2. Pharmaceutical compositions using these compounds are prepared to treat or prevent diseases involving the EP4 receptor, such as abdominal aortic aneurysm, ankylosing spondylitis, Alzheimer's disease, atherosclerosis, epithelial carcinoma, diabetic nephropathy, endometriosis, inflammatory bowel disease, migraine, multiple sclerosis, osteoarthritis, and rheumatoid arthritis.
These compounds, as EP4 antagonists, can effectively treat or prevent related diseases, providing clinical benefits while reducing side effects, achieving a risk-benefit balance that cannot be achieved with existing COX inhibitors.
Smart Images

Figure CN114585603B_ABST
Abstract
Description
[0001] The present application relates to novel compounds and their use as prostaglandin E2 receptor 4 (EP4) antagonists. The compounds described herein can be used to treat or prevent diseases in which the EP4 receptor is involved. The application also relates to pharmaceutical compositions comprising these compounds, as well as the manufacture of these compounds and compositions and their use in preventing or treating such diseases in which the EP4 receptor is involved. Background of the Invention
[0003] Prostaglandins (PGs) are small molecule (~400 Da) products generated by cyclooxygenases (COX; constitutively active COX1 and inducible COX2) and PG synthases, with a small contribution from the isoprostane pathway, acting on arachidonic acid (AA). Prostaglandin E2 (PGE2) is the major COX product in bone marrow and stromal cells, and its levels are determined by the balance between synthesis and degradation mediated by 15-hydroxyprostaglandin dehydrogenase (15-PGDH). PGE2 has 4 kinds of receptors (EP1-EP4), and the receptor is present in various cell types, including macrophage, monocyte, platelet, sensory neuron, gastrointestinal tract, kidney, thymus, heart, lung and uterus; And drive extensive pharmacological mediation nociception, the regulation of neuronal signal conduction aspect, hematopoiesis, blood flow, kidney filtration and blood pressure, the regulation of mucosal integrity, vascular permeability, smooth muscle function and proinflammatory immune function (mast cell, macrophage and neutrophil vasodilation, raising (recruitment) and activation) and immunosuppressive immune function (described in detail hereinafter). Functional PGE2 antagonism has therapeutic potential in various disease environments, discussed hereinafter.
[0004] Abdominal aortic aneurysm (AAA). AAA is a life-threatening inflammatory vascular disease associated with connective tissue degeneration and loss of smooth muscle in a dilated aorta that is prone to rupture. Diseased aortic tissue is associated with expression of EP4, PGE2, and expression of macrophages and smooth muscle COX2 (Walton, LJ et al. Circulation 100, 48-54 (1999)). EP4 antagonism or gene deletion is associated with beneficial results in human and mouse preclinical systems (Yokoyama, U. et al. PLoS One 7, e36724 (2012)).
[0005] Ankylosing spondylitis (AS). AS is a heritable autoimmune disease associated with HLA-B27 and EP4. Inflammatory pain in rodent models can be driven by PGE2 and EP4. The pain in AS patients is NSAID responsive, which suggests that EP4 antagonists can also be analgesics for AS, with long-term safety benefits associated with specific EP4 antagonism relative to general AA metabolic inhibition, as discussed below in the cancer section (Murase, A. et al. Eur. J. Pharmacol. 580, 116-121 (2008)).
[0006] Alzheimer's disease (AD). Amyloid-β peptide (Aβ) produced by the hydrolysis of β-amyloid precursor protein (APP) mediated by β-secretase and γ-secretase plays a key role in AD pathogenesis. PGE2 stimulates Aβ production by endocytosis and activation of γ-secretase. Transgenic mice expressing mutant APP (APP23) hybridized with EP4-deficient mice have been shown to exhibit lower levels of Aβ plaque deposition and less neuron and synapse loss than control mice. Oral treatment with specific EP4 has been shown to improve cognitive performance and reduce Aβ levels in the brain (Hoshino, T. et al. J. Neurochem. 120, 795-805 (2012)).
[0007] Atherosclerosis. EP4 has been associated with the instability of human atherosclerotic plaques via PGE2 induction of MMP-2 and MMP-9 (Cipollone, F. et al. Arterioscler. Thromb. Vasc. Biol. 25, 1925-31 (2005)). By analyzing EP4-deficient macrophages that have been damaged in mouse models, EP4 has also been validated as a target for preventing the development of atherosclerosis (Babaev, VR et al. Cell Metab. 8, 492-501 (2008)).
[0008] Cancer. Cancer or neoplasms are the leading causes of mortality and morbidity worldwide. The literature strongly supports a role for PGE2 in epithelial cancers (GBD neoplasms of colon and rectum, lip and oral cavity, nasopharynx, other pharynx, gallbladder and biliary tract, pancreas, non-melanoma skin, ovary, testis, kidney, bladder, thyroid, mesothelioma, esophagus, stomach, liver, larynx, trachea, bronchi and lung, breast, cervix, uterus, prostate).
[0009] PGE2 and related receptors are upregulated in a variety of epithelial neoplasms (colon cancer, lip and oral cancer, gallbladder cancer, pancreatic cancer, non-melanoma skin cancer, ovarian cancer, kidney cancer, bladder cancer, thyroid cancer, mesothelioma, esophageal squamous cell carcinoma, gastric cancer, liver cancer, squamous cell lung cancer, breast cancer, triple-negative breast cancer, cervical cancer, uterine cancer, prostate cancer, head and neck squamous cell carcinoma), and expression levels are associated with disease progression (lip and oral cancer, esophageal squamous cell carcinoma, cervical cancer, prostate cancer, head and neck squamous cell carcinoma).
[0010] The use of celecoxib (a COX-2 selective inhibitor) has been shown to reduce the incidence of adenoma development and the rate of advanced adenoma development, but increases serious cardiovascular events in participants who have had adenoma removed (Arber, N. et al. N. Engl. J. Med. 355, 885–895 (2006)). Celecoxib has also been tested as a combination therapy for a variety of cancers. A meta-analysis of 5 randomized trials using aspirin (a COX-1 inhibitor and a COX-2 inhibitor) has shown that a dose of at least 75 mg per day reduces the risk of colon cancer over 20 years (Rothwell, PM et al. Lancet 376, 1741–1750 (2010)). PI3K mutations are present in 15%-20% of colorectal cancers (CRC) with multiple activations; PI3K upregulation enhances PTGS2 (COX-2) activity and therefore enhances PGE2 synthesis. Regular aspirin use after CRC diagnosis is associated with a survival benefit in patients with mutant PIK3CA but not wild-type PIK3CA (Liao, X. et al. N. Engl. J. Med. 367, 1596-1606 (2012)).
[0011] The therapeutic utility of COX inhibitors is subject to the limitation of the potentiality that it causes GI (NSAID such as aspirin) or CV (NSAID and coxibs (Coxibs) such as celecoxib) toxicity.Therefore, although the effectiveness of aspirin and NSAID in cancer chemoprevention usually has been approved by international consensus, the risk / benefit ratio is still challenging, and therefore not yet made clear and definite use suggestion.In a word, these data show that the broad spectrum inhibition of prostaglandin synthesis is a kind of too rigid pharmacological tool to achieve suitable benefit: risk balance, and there is the demand for more specific medicine to be evaluated.Therefore, we assume that by EP4 antagonism, specifically neutralize PGE2 biology and clinical benefit will be provided, and the side effect profile is minimized simultaneously.
[0012] PGE2 represents an attractive therapeutic target, which drives immunosuppressive processes, immunological processes and oncological processes to promote cancer development and progression.COX-2 and epidermal growth factor receptor (EGFR) pathways are activated in most human cancers.When human colorectal cancer (CRC) cells are transfected with COX2, they are induced and proliferated in conjunction with EGFR, which shows crosstalk between pathways.When PGE2 neutralizing antibodies are administered, mice carrying CRC tumors have shown reduced tumor growth (Stolina, M. et al. J. Immunol. 164, 361–70 (2000)). PGE2 is usually anti-apoptotic under hypoxia and treatment (such as radiotherapy) conditions, and activates Ras-MAPK / ERK and PI3K / AKT survival pathways (Wang, D. & Dubois, RNGut 55, 115–22 (2006)).Preclinical rodent studies and human studies support the view that PGE2 plays a key role in cancer development and progression, and have begun to elucidate mechanisms. COX expression in tumor produces PGE2 that destroys myeloid function;COX ablation using knockout or aspirin / coxibs enables immune control of tumors, and COX inhibition and immune checkpoint blockade synergistically in the form of PD1 blocking antibodies (Zelaney et al., Cell, 2015). These data show that other known immune checkpoint blockers can inhibit synergy with PGE2. Finally, COX inflammatory signatures are conservative in mice and human cancer biopsies (Zelaney et al., Cell, 2015). It is highly possible that the coxibs dose required for completely suppressing PGE2 in the tumor microenvironment exceeds the coxibs dose licensed for clinical use in people, which further supports the demand for drugs that block the cancer support biology of PGE2 without producing dose-limiting toxicity.
[0013] A variety of immune cells carry adenosine receptors (mainly A2 A and A2 B ), which acts like EP2 and EP4 to increase intracellular cAMP and mediate immunosuppression. PGE2 and adenosine are co-expressed in neoplasms, supporting the concept that clinical benefit will result from combining PGE2 and adenosine pathway modulators.
[0014] These findings suggest that functional antagonism of PGE2 has strong potential to provide both strong clinical benefit to patients with a variety of epithelial cancers but also to synergize with current standards of care and new IO agents under development.
[0015] Diabetic nephropathy. Diabetes is associated with a variety of macrovascular complications including nephropathy, retinopathy and neuropathy. Diabetic nephropathy is the main cause of end-stage renal disease, is associated with high cardiovascular risk, and is a common sequela of about 1 / 3 of diabetic patients. Current therapy focuses on the control of blood sugar and blood pressure to minimize the key risk factors of hyperglycemia, hypertension, dyslipidemia, obesity, but is not effective enough. PGE2 is the most abundant renal prostaglandin and plays a variety of roles in the following renal physiology: inflammation, volume homeostasis, regulation of salt and water balance, renal blood flow, renin release, glomerular hemodynamics (Breyer, MD, Jacobson, HR & Breyer, RMJAm.Soc.Nephrol.7, 8-17 (1996)); EP1 and EP3 are usually vasoconstrictive, while EP2 and EP4 mediate vasodilation. EP4 has been involved in mediating renal damage in preclinical models that simulate aspects of diabetic nephropathy. Four weeks of repeated oral administration of the EP4 antagonist ASP7657 has been shown to dose-dependently attenuate proteinuria in type 2 diabetic db / db mice (Mizukami, K. et al. Naunyn. Schmiedebergs. Arch. Pharmacol. 391, 1319-1326 (2018)).
[0016] Endometriosis. Endometriosis is characterized by persistent colonization of endometrial tissue outside the uterine cavity, possibly via retrograde menstrual blood flow, resulting in the formation of typical lesions and "endometriotic lesions" with upregulated COX2 and elevated PGE2.
[0017] PGE2 stimulates the adhesion of integrin-mediated endometriotic epithelial cells and stromal cells via EP2 and EP4, and drives the proliferation of endometriotic epithelial cells and stromal cells; When PGE2 is blocked, this drives apoptosis. Data show that EP4 antagonism may have therapeutic utility in endometriosis (Lee, J., Banu, SK, Burghardt, RC, Starzinski-Powitz, A. & Arosh, JA Biol. Reprod. 88, 77 (2013)).
[0018] Inflammatory bowel disease. PGE2 directly promotes the differentiation and pro-inflammatory function of IL-17-producing T helper (Th17) cells (Boniface et al., JEM, 2009) via upregulation of the IL-23 receptor associated with driving IBD (Lee et al., JACI, 2019); IL-12 / 23 neutralizing ustekinumab is effective in ulcerative colitis and Crohn's disease.
[0019] Migraine. PGE2 has strong target validation in migraine. PGE2 is upregulated in jugular blood, plasma and saliva of people experiencing migraine. IV infusion of prostaglandins can induce migraine symptoms in migraine patients; PGE2 relaxes human cerebral arteries in an EP4-dependent manner (Maubach, KAKA et al. Br. J. Pharmacol. 156, 316-327 (2009)). In vitro and in vivo chemical stimulation of dura mater, trigeminal neurons, afferent nerves and sensory afferent nerves causes PGE2 release. PGE2 induces an increase in peptide release and sensitization of sensory neurons via EP4 (Southall, MD & Vasko, MRJ Biol. Chem. 276, 16083-91 (2001)). These data indicate that EP4 antagonists may have therapeutic utility in the treatment of migraine.
[0020] Multiple sclerosis (MS). PGE2 levels are clearly detected in MS cerebrospinal fluid (CSF), but cannot be detected in CSF from people who do not suffer from neurological diseases. It is predicted that functional PGE2 antagonists provide clinical benefits of MS via the inhibition of IL-23 production and the inhibition of Th1 cells and Th17 cell development (Cua, DJ et al. Nature 421,744-8 (2003)).
[0021] Osteoarthritis (OA). PGE2 is upregulated in synovial fluid and cartilage from OA patients, and PGE2 stimulates matrix degradation on OA chondrocytes via EP4 (Attur, M. et al. J. Immunol. 181, 5082-8 (2008)).
[0022] Osteoporosis. PGE2 plays a key role in driving bone resorption, primarily through EP4. Bone loss is often observed when tumors metastasize to the bone; preclinical data from a breast metastasis model show that EP4 antagonism reduces the loss of bone mineral density (Takita, M., Inada, M., Maruyama, T. & Miyaura, C. FEBS Lett. 581, 565-571 (2007)).
[0023] Overactive bladder. Cyclophosphamide injection induces overactive bladder in rats. EP4 antagonists administered either simultaneously, systemically or directly into bladder tissue have been shown to reduce bladder inflammation and the frequency of bladder contractions (overactivity) (Chuang, Y.-C., Tyagi, P., Huang, C.-C., Chancellor, MB & Yoshimura, N. BJU Int. 110, 1558-1564 (2012)).
[0024] Rheumatoid arthritis. PGE2 can act as both an immunosuppressant and an immunostimulator and should probably be considered a context-dependent immunomodulator. EP4-deficient mice show significant differences in immune function compared to WT or EP 1-3 Deficient mice have been shown to develop reduced arthritis symptoms in the CAIA model, which is clearly related to EP4 (McCoy, JM, Wicks, JR & Audoly, LP J Clin. Invest. 110, 651-658 (2002)).
[0025] The data suggest that functional antagonism of PGE2 has the potential to improve the clinically relevant Th17 axis in rheumatoid arthritis and thus provide strong clinical benefit.
[0026] The invention described herein relates to new compounds and their use as EP4 antagonists. The compounds described herein can be used to treat or prevent diseases in which the EP4 receptor is involved. The invention also relates to pharmaceutical compositions comprising these compounds, as well as the manufacture of these compounds and compositions and their use in preventing or treating such diseases in which the EP4 receptor is involved. Therefore, the compounds of the present invention can be used to treat abdominal aortic aneurysm (AAA), ankylosing spondylitis (AS), Alzheimer's disease (AD), atherosclerosis, cancers including epithelial cancers (GBD neoplasms of colon and rectum, lip and oral cavity, nasopharynx, other pharynx, gallbladder and bile duct, pancreas, non-melanoma skin, ovary, testis, kidney, bladder, thyroid, mesothelioma, esophagus, stomach, liver, larynx, trachea, bronchi and lung, breast, cervix, uterus, prostate), diabetic nephropathy, endometriosis, inflammatory bowel disease, migraine, multiple sclerosis (MS), osteoarthritis (OA) and rheumatoid arthritis.
[0027] The compounds of the invention may be used as a single therapeutic agent or in combination with one or more other therapeutic agents of any type. For the treatment or prevention of cancer, this may include radiotherapy and / or chemotherapy and / or immunotherapy and / or other oncology modulators.
[0028] invention
[0029] The present invention provides compounds having activity as prostaglandin E2 receptor 4 (EP4) antagonists.
[0030] The present invention provides a compound of formula (1):
[0031]
[0032] or a salt thereof, wherein:
[0033] A is selected from the group consisting of:
[0034]
[0035] X is an optionally substituted phenyl ring, an optionally substituted pyridyl ring or an optionally substituted imidazopyridine ring system;
[0036] R 1 and R 2 is independently H or C optionally substituted by one or more fluorine atoms 1-3 an alkyl group; or R 1 and R 2 are connected to form a 3-6 membered carbocyclic ring, wherein the 3-6 membered carbocyclic ring is optionally substituted with one or more fluorine atoms;
[0037] R 3 It is H, C 1-3 Alkyl or F;
[0038] R 4 Is H or C 1-3 alkyl;
[0039] R 8 It is C 1-3 Alkyl or C 3-6 Cycloalkyl ring;
[0040] And R 10 and R 11 Both are methyl, or R 10 and R 11 are connected to form a cyclobutyl ring.
[0041] The compound can be used as an EP4 receptor antagonist. The compound can be used to manufacture a drug. The compound or drug can be used to treat, prevent, improve, control, or reduce the risk of a disease or disorder involving an EP4 receptor. Therefore, the compound of the present invention can be used to treat abdominal aortic aneurysm (AAA), ankylosing spondylitis (AS), Alzheimer's disease (AD), atherosclerosis, cancers including epithelial cancers (GBD neoplasms of colon and rectum, lip and oral cavity, nasopharynx, other pharynx, gallbladder and bile duct, pancreas, non-melanoma skin, ovary, testis, kidney, bladder, thyroid, mesothelioma, esophagus, stomach, liver, larynx, trachea, bronchi and lung, breast, cervix, uterus, prostate), diabetic nephropathy, endometriosis, inflammatory bowel disease, migraine, multiple sclerosis (MS), osteoarthritis (OA) and rheumatoid arthritis. DETAILED DESCRIPTION OF THE INVENTION
[0043] The present invention relates to novel compounds, the use of novel compounds as EP4 receptor antagonists, and the use of novel compounds in the manufacture of drugs used as EP4 receptor antagonists.
[0044] The present invention also relates to compounds, compositions and medicaments for treating abdominal aortic aneurysm (AAA), ankylosing spondylitis (AS), Alzheimer's disease (AD), atherosclerosis, cancers including epithelial cancers (GBD neoplasms of colon and rectum, lip and oral cavity, nasopharynx, other pharynx, gallbladder and biliary tract, pancreas, non-melanoma skin, ovary, testis, kidney, bladder, thyroid, mesothelioma, esophagus, stomach, liver, larynx, trachea, bronchi and lung, breast, cervix, uterus, prostate), diabetic nephropathy, endometriosis, inflammatory bowel disease, migraine, multiple sclerosis (MS), osteoarthritis (OA) and rheumatoid arthritis.
[0045] The present invention provides a compound of formula (1):
[0046]
[0047] or a salt thereof, wherein:
[0048] A is selected from the group consisting of:
[0049]
[0050] X is an optionally substituted phenyl ring, an optionally substituted pyridyl ring or an optionally substituted imidazopyridine ring system;
[0051] R 1 and R 2 is independently H or C optionally substituted by one or more fluorine atoms 1-3 an alkyl group; or R 1 and R 2 are connected to form a 3-6 membered carbocyclic ring, wherein the 3-6 membered carbocyclic ring is optionally substituted with one or more fluorine atoms;
[0052] R 3 It is H, C 1-3 Alkyl or F;
[0053] R 4 Is H or C 1-3 alkyl;
[0054] R 8 It is C 1-3 Alkyl or C 3-6 Cycloalkyl ring;
[0055] And R 10 and R 11 Both are methyl, or R 10 and R 11 are connected to form a cyclobutyl ring.
[0056] Also provided are compounds of formula (1a):
[0057]
[0058] or a salt thereof, wherein:
[0059] A is selected from the group consisting of:
[0060]
[0061] X is an optionally substituted phenyl ring, an optionally substituted pyridyl ring or an optionally substituted imidazopyridine ring system;
[0062] R 1 and R 2 is independently H or C optionally substituted by one or more fluorine atoms 1-3 an alkyl group; or R 1 and R 2 are connected to form a 3-6 membered carbocyclic ring, wherein the 3-6 membered carbocyclic ring is optionally substituted with one or more fluorine atoms;
[0063] R 3 It is H, C 1-3 Alkyl or F;
[0064] R 4 Is H or C 1-3 alkyl;
[0065] And R 8 It is C 1-3 Alkyl or C 3-6 Cycloalkyl ring.
[0066] Also provided are compounds of formula (1b):
[0067]
[0068] or a salt thereof, wherein:
[0069] A is selected from the group consisting of:
[0070]
[0071] X is an optionally substituted phenyl ring, an optionally substituted pyridyl ring or an optionally substituted imidazopyridine ring system;
[0072] R 1 and R 2 is independently H or C optionally substituted by one or more fluorine atoms 1-3 an alkyl group; or R 1 and R 2are connected to form a 3-6 membered carbocyclic ring, wherein the 3-6 membered carbocyclic ring is optionally substituted with one or more fluorine atoms;
[0073] R 3 It is H, C 1-3 Alkyl or F;
[0074] R 4 Is H or C 1-3 alkyl;
[0075] And R 8 It is C 1-3 Alkyl or C 3-6 Cycloalkyl ring;
[0076] The present invention provides a compound of formula (1c):
[0077]
[0078] or a salt thereof, wherein:
[0079] A is selected from the group consisting of:
[0080]
[0081] X is an optionally substituted phenyl ring, an optionally substituted pyridyl ring or an optionally substituted imidazopyridine ring system;
[0082] R 1 and R 2 is independently H or C optionally substituted by one or more fluorine atoms 1-3 an alkyl group; or R 1 and R 2 are connected to form a 3-6 membered carbocyclic ring, wherein the 3-6 membered carbocyclic ring is optionally substituted with one or more fluorine atoms;
[0083] R 4 Is H or C 1-3 alkyl;
[0084] R 8 It is C 1-3 Alkyl or C 3-6 Cycloalkyl ring;
[0085] And R 10 and R 11 Both are methyl, or R 10 and R 11 are connected to form a cyclobutyl ring.
[0086] Specific compounds include compounds of formula (2) and formula (2i):
[0087]
[0088] or a salt thereof, wherein:
[0089] A.R 1 , R 2 , R 3 and R 4 As defined above;
[0090] Q, W and T are CH or N;
[0091] Z and Y are C or N;
[0092] Where any or none of Q, W, T, Y, and Z is N, and if Y is N, then R 5 does not exist, and if Z is N, then R 6 does not exist;
[0093] R 5 and R 6 Independently selected from H, halogen, CN, OH, SF5, C 1-6 Alkyl, C 3-6 Cycloalkyl, C 1-6 Alkoxy, OR 7 and SO2R 7 , wherein the alkyl group, the cycloalkyl group and the alkoxy group are optionally substituted by one or more fluorine atoms, and any one atom in the alkyl group or the cycloalkyl group may be optionally replaced by a heteroatom selected from O, S and N; or R 5 and R 6 are connected to form a 5-membered or 6-membered carbocyclic or heterocyclic ring, the 5-membered or 6-membered carbocyclic or heterocyclic ring being optionally substituted with one or more fluorine atoms; and R 7 is C optionally substituted by one or more fluorine atoms 1-6 An alkyl group or a C 3-6 Cycloalkyl groups.
[0094] Specific compounds include compounds of formula (2a) and formula (2b):
[0095]
[0096] and salts thereof, wherein A, T, Y, Z, Q, W, R 1 , R 2 , R 5 and R 6 As defined above.
[0097] Specific compounds include compounds of formula (2ia) and formula (2ib):
[0098]
[0099] and salts thereof, wherein A, T, Y, Z, Q, W, R 1 , R 2 , R 5 and R 6 As defined above.
[0100] Specific compounds include compounds of formula (3), formula (3a), formula (3b), formula (3i), formula (3ia), and formula (3ib):
[0101]
[0102] and salts thereof, wherein A, T, Y, Z, Q, W, R 1 , R 2 , R 3 , R 4 , R 5 and R 6 As defined above.
[0103] Specific compounds include compounds of formula (4), formula (4a), formula (4b), formula (4i), formula (4ia) and formula (4ib):
[0104]
[0105] and salts thereof, wherein A, T, Y, Z, Q, W, R 3 , R 4 , R 5 and R 6 As defined above.
[0106] Specific compounds include compounds of formula (5), formula (5a), formula (5b), formula (5i), formula (5ia) and formula (5ib):
[0107]
[0108] and salts thereof, wherein A, T, Y, Z, Q, W, R 3 , R 4 , R 5 and R 6 As defined above.
[0109] Specific compounds include compounds of formula (6), formula (6a), formula (6b), formula (6c), formula (6d), formula (6e), formula (6f), formula (6g), formula (6h), formula (6j), formula (6k) and formula (6l):
[0110]
[0111] and its salts, wherein A, R 1 , R2 , R 3 , R 4 , R 5 and R 6 As defined above.
[0112] Specific compounds include compounds of formula (6i), formula (6ia), formula (6ib), formula (6ic), formula (6id), formula (6ie), formula (6if), formula (6ig), formula (6ih), formula (6ij), formula (6ik) and formula (6il):
[0113]
[0114] and its salts, wherein A, R 1 , R 2 , R 3 , R 4 , R 5 and R 6 As defined above.
[0115] The compound may be a compound of formula (7):
[0116]
[0117] and its salts, wherein X, R 1 , R 2 , R 3 , R 4 , R 10 and R 11 As defined above.
[0118] In the compounds herein, A may be selected from:
[0119]
[0120] In the compounds herein, A may be selected from the group consisting of CO2H, tetrazole, 1,2,4-oxadiazol-5(2H)-one, 1,3,4-oxadiazol-2(3H)-one, CONHS02R 8 , CONHSO2Me, SO3H, 1,3,4-oxadiazole-2(3H)-thione, 1,2,4-oxadiazole-5(2H)-thione, 1,2,4-thiadiazole-5(2H)-one, 1,2,5-thiadiazolidine-3-one 1,1-dioxide and 2,4-oxazolidinedione.
[0121] In the compounds herein, A may be selected from CO2H, CONHSO2Me and a tetrazole ring. A may be CO2H. A may be CONHSO2Me. A may be a tetrazole ring.
[0122] In the compounds herein, R 1 and R 2 may independently be H or C optionally substituted by one or more fluorine atoms 1-3 Alkyl group. 1 and R 2 can be connected to form a 3-6 membered carbocyclic ring, which is optionally substituted with one or more fluorine atoms.
[0123] In the compounds herein, R 1 It can be H. R 1 It may be C optionally substituted by one or more fluorine atoms. 1-3 Alkyl group. 1 Can be used with R 2 are connected to form a 3-6 membered carbon ring which is optionally substituted with one or more fluorine atoms. 1 Can be used with R 2 Connected to form a 3-6 membered carbon ring. 1 It may be C optionally substituted by 1 to 3 fluorine atoms. 1-3 Alkyl group. 1 Can be C 1-3 Alkyl group. 1 It can be methyl. 1 Can be used with R 2 Connect to form a cyclopropyl ring.
[0124] In the compounds herein, R 2 It can be H. R 2 It may be C optionally substituted by one or more fluorine atoms. 1-3 Alkyl group. 2 Can be used with R 1 are connected to form a 3-6 membered carbon ring which is optionally substituted with one or more fluorine atoms. 2 Can be used with R 1 Connected to form a 3-6 membered carbon ring. 2 It may be C optionally substituted by 1 to 3 fluorine atoms. 1-3 Alkyl group. 2 Can be C 1-3 Alkyl group. 2 It can be methyl. 2 Can be used with R 1 Connect to form a cyclopropyl ring.
[0125] In the compounds herein, R 1 can be methyl, and R 2 It can be H. R 1 and R 2 Both can be methyl. 1 and R 2Both can be H. R 1 and R 2 Can be linked to form a cyclopropyl ring.
[0126] In the compounds herein, R 3 Can be H, C 1-3 Alkyl or F. R 3 It can be H, methyl or F. R 3 Can be C 1-3 Alkyl. 3 It can be methyl. 3 It can be H. R 3 It can be F.
[0127] In the compounds herein, R 4 Can be H or C 1-3 Alkyl. 4 It can be H or methyl. 4 Can be C 1-3 Alkyl. 4 It can be methyl. 4 It can be H.
[0128] In the compounds herein, X may be an optionally substituted phenyl ring. X may be an optionally substituted pyridyl ring. X may be an optionally substituted imidazopyridine ring system.
[0129] In the compounds herein, X may be any of the following ring systems which may be optionally substituted:
[0130]
[0131] In the compounds herein, X may be:
[0132]
[0133] Among them, T, Y, Z, Q, W, R 5 and R 6 As defined above.
[0134] In the compounds herein, X may be selected from the group consisting of:
[0135]
[0136] Where R 5 and R 6 As defined above.
[0137] In the compounds herein, R 5 and R 6 can be independently selected from H, halogen, CN, OH, SF5, C 1-6 Alkyl, C3-6 Cycloalkyl, C 1-6 Alkoxy, OR 7 and SO2R 7 , wherein the alkyl group, the cycloalkyl group and the alkoxy group are optionally substituted by one or more fluorine atoms, and any one atom in the alkyl group or the cycloalkyl group may be optionally replaced by a heteroatom selected from O, S and N; R 5 and R 6 can be connected to form a 5-membered or 6-membered carbocyclic or heterocyclic ring, which is optionally substituted by one or more fluorine atoms. 5 and R 6 It can be independently selected from H, Cl, F, CN, OH, SO2Me, SO2Et, SO2-cyclopropyl, SF5, CF3, CF2H, OMe, OCF3, OCF2H, CH2OH, CH2OMe, cyclopropyl and oxetanyl.
[0138] In the compounds herein, R 5 Can be selected from H, halogen, CN, OH, SF5, OR 7 and SO2R 7 . R 5 Can be C 1-6 Alkyl, C 1-6 Alkoxy or C 3-6 Cycloalkyl, wherein the alkyl group, the cycloalkyl group and the alkoxy group are optionally substituted by one or more fluorine atoms, and any one atom in the alkyl group or the cycloalkyl group may be optionally replaced by a heteroatom selected from O, S and N. 5 Can be C 1-6 Alkyl, C 1-6 Alkoxy or C 3-6 Cycloalkyl, wherein the alkyl group, cycloalkyl group and alkoxy group are optionally substituted by one or more fluorine atoms. 5 Can be C 1-6 Alkyl, C 1-6 Alkoxy or C 3-6 Cycloalkyl. 5 R may be selected from H, Cl, F, CN, OH, SO2Me, SO2Et, SO2-cyclopropyl, SF5, CF3, CF2H, OMe, OCF3, OCF2H, CH2OH, CH2OMe, cyclopropyl and oxetanyl. 5 It can be H. R 5 Can be CF3 or F. R 5 It can be CF3. 5 It can be F. R 5 Can be used with R 6are connected to form a 5-membered or 6-membered carbocyclic or heterocyclic ring optionally substituted by one or more fluorine atoms. 5 Can be used with R 6 Connected to form a fused dioxolanering optionally substituted with one or two fluorine atoms. 5 Can be used with R 6 Connected to form a fused dioxolane ring. 5 Can be used with R 6 connected to form a fused dioxolane ring substituted with one or two fluorine atoms. 5 Can be used with R 6 Connected to form a fused dioxolane ring substituted with two fluorine atoms. 5 and R 6 Can be linked to form a fused imidazole ring. 5 and R 6 can be linked to form, together with the ring to which they are attached, an imidazo[1,2-a]pyridine ring system.
[0139] In the compounds herein, R 6 Can be selected from H, halogen, CN, OH, SF5, OR 7 and SO2R 7 . R 6 Can be C 1-6 Alkyl, C 1-6 Alkoxy or C 3-6 Cycloalkyl, wherein the alkyl group, the cycloalkyl group and the alkoxy group are optionally substituted by one or more fluorine atoms, and any one atom in the alkyl group or the cycloalkyl group may be optionally replaced by a heteroatom selected from O, S and N. 6 Can be C 1-6 Alkyl, C 1-6 Alkoxy or C 3-6 Cycloalkyl, wherein the alkyl group, cycloalkyl group and alkoxy group are optionally substituted by one or more fluorine atoms. 6 Can be C 1-6 Alkyl, C 1-6 Alkoxy or C 3-6 Cycloalkyl. 6 R may be selected from H, Cl, F, CN, OH, SO2Me, SO2Et, SO2-cyclopropyl, SF5, CF3, CF2H, OMe, OCF3, OCF2H, CH2OH, CH2OMe, cyclopropyl and oxetanyl. 6 It can be H. R 6 Can be CF3 or F. R 6 It can be CF3. 6 It can be F. R6 Can be used with R 5 are connected to form a 5-membered or 6-membered carbocyclic or heterocyclic ring optionally substituted by one or more fluorine atoms. 6 Can be used with R 5 are connected to form a fused dioxolane ring optionally substituted with one or two fluorine atoms. 6 Can be used with R 5 Connected to form a fused dioxolane ring. 6 Can be used with R 5 connected to form a fused dioxolane ring substituted with one or two fluorine atoms. 6 Can be used with R 5 Connected to form a fused dioxolane ring substituted with two fluorine atoms. 6 and R 5 Can be linked to form a fused imidazole ring. 6 and R 5 can be linked to form, together with the ring to which they are attached, an imidazo[1,2-a]pyridine ring system.
[0140] In the compounds herein, Q, W and T may be CH or N. Z and Y may be C or N.
[0141] In the compounds herein, any or none of Q, W, T, Y and Z is N. If Y is N, then R 5 does not exist. If Z is N, then R 6 Does not exist.
[0142] In the compounds herein, Q, W and T may be CH, and Z and Y may be C. Q, W and T may be CH, Z may be C, and Y may be N. Q, W and T may be CH, Z may be N, and Y may be C. Q and W may be CH, T may be N, and Z and Y may be C. Q and T may be CH, W may be N, and Z and Y may be C. T and W may be CH, Q may be N, and Z and Y may be C.
[0143] In the compounds herein, R 7 It may be C optionally substituted by one or more fluorine atoms. 1-6 Alkyl group. 7 It may be C optionally substituted by one or more fluorine atoms. 3-6 Cycloalkyl group. 7 Can be C 1-6 Alkyl group. 7 Can be C 3-6 Cycloalkyl group. 7 It can be methyl. 7 It can be ethyl.7 It can be CF3. 7 It can be CF2H.
[0144] In the compounds herein, R 8 Can be C 1-3 Alkyl. 8 Can be C 3-6 Cycloalkyl. 8 It may be methyl.
[0145] In the compounds herein, R 10 and R 11 Both can be methyl, or R 10 and R 11 Can be linked to form a cyclobutyl ring. 10 It can be methyl or with R 11 Connect to form a cyclobutyl ring. 11 It can be methyl or with R 10 Connect to form a cyclobutyl ring.
[0146] The compound may be selected from any one of Examples 1 to 101 shown in Table 1 or a salt thereof.
[0147] The compound may be selected from the group consisting of:
[0148] 4-((S)-1-((R)-3-methyl-2-((4-(trifluoromethyl)benzyl)oxy)butyrylamino)ethyl)benzoic acid;
[0149] (R)-4-(1-(3-methyl-2-((4-(trifluoromethyl)benzyl)oxy)butyrylamino)cyclopropyl)benzoic acid;
[0150] 4-((1S)-1-(2-((3-methoxybenzyl)oxy)-3-methylbutyrylamino)ethyl)benzoic acid;
[0151] 4-((S)-1-((S)-2-((4-fluorobenzyl)oxy)-3-methylbutyrylamino)ethyl)benzoic acid;
[0152] 4-((S)-1-((R)-2-((4-fluorobenzyl)oxy)-3-methylbutyrylamino)ethyl)benzoic acid;
[0153] 4-((1S)-1-(2-((4-methoxybenzyl)oxy)-3-methylbutyrylamino)ethyl)benzoic acid;
[0154] 4-((S)-1-((S)-3-methyl-2-((3-(methylsulfonyl)benzyl)oxy)butyrylamino)ethyl)benzoic acid;
[0155] 4-((S)-1-((R)-3-methyl-2-((3-(methylsulfonyl)benzyl)oxy)butyrylamino)ethyl)benzoic acid;
[0156] 4-((S)-1-((S)-3-methyl-2-((4-(methylsulfonyl)benzyl)oxy)butyrylamino)ethyl)benzoic acid;
[0157] 4-((S)-1-((R)-3-methyl-2-((4-(methylsulfonyl)benzyl)oxy)butyrylamino)ethyl)benzoic acid;
[0158] 4-((S)-1-((R)-2-((4-chlorobenzyl)oxy)-3-methylbutyrylamino)ethyl)benzoic acid;
[0159] 4-((S)-1-((R)-2-((3-chlorobenzyl)oxy)-3-methylbutyrylamino)ethyl)benzoic acid;
[0160] 4-((S)-1-((R)-2-((4-(difluoromethyl)benzyl)oxy)-3-methylbutyrylamino)ethyl)benzoic acid;
[0161] 4-((S)-1-((R)-2-((3-(difluoromethyl)benzyl)oxy)-3-methylbutyrylamino)ethyl)benzoic acid;
[0162] 4-((S)-1-((R)-3-methyl-2-((3-(trifluoromethyl)benzyl)oxy)butyrylamino)ethyl)benzoic acid;
[0163] 4-((S)-1-((S)-3-methyl-2-((4-(trifluoromethyl)benzyl)oxy)butyrylamino)ethyl)benzoic acid;
[0164] 4-((1S)-1-(2-((3-fluorobenzyl)oxy)-3-methylbutyrylamino)ethyl)benzoic acid;
[0165] 4-((S)-1-((R)-2-(Benzyloxy)-3-methylbutyrylamino)ethyl)benzoic acid;
[0166] 4-((S)-1-((R)-3-methyl-2-((3-(trifluoromethoxy)benzyl)oxy)butyrylamino)ethyl)benzoic acid;
[0167] 4-((S)-1-((R)-2-((4-cyanobenzyl)oxy)-3-methylbutyrylamino)ethyl)benzoic acid;
[0168] 4-((S)-1-((R)-2-((3-cyanobenzyl)oxy)-3-methylbutyrylamino)ethyl)benzoic acid;
[0169] 4-((S)-1-((R)-2-((4-(difluoromethoxy)benzyl)oxy)-3-methylbutyrylamino)ethyl)benzoic acid;
[0170] 4-((S)-1-((R)-2-((3-(difluoromethoxy)benzyl)oxy)-3-methylbutyrylamino)ethyl)benzoic acid;
[0171] 4-((S)-1-((R)-3-methyl-2-((5-(trifluoromethyl)pyridin-2-yl)methoxy)butyrylamino)ethyl)benzoic acid;
[0172] 4-((S)-1-((R)-3-methyl-2-((4-(pentafluoro-λ 6 -sulfanyl)benzyl)oxy)butyrylamino)ethyl)benzoic acid;
[0173] 4-((S)-1-((R)-2-((3,4-difluorobenzyl)oxy)-3-methylbutyrylamino)ethyl)benzoic acid;
[0174] 4-((S)-1-((R)-2-((2,2-difluorobenzo[d][1,3]dioxol-5-yl)methoxy)-3-methylbutyrylamino)ethyl)benzoic acid;
[0175] 4-((S)-1-((R)-2-((4-(difluoromethyl)-3-fluorobenzyl)oxy)-3-methylbutyrylamino)ethyl)benzoic acid;
[0176] 4-((S)-1-((R)-2-((4-cyclopropylbenzyl)oxy)-3-methylbutyrylamino)ethyl)benzoic acid;
[0177] (R)-4-(1-(2-((4-fluorobenzyl)oxy)-3-methylbutyrylamino)cyclopropyl)benzoic acid;
[0178] 4-((S)-1-((R)-2-((3-(difluoromethoxy)-4-fluorobenzyl)oxy)-3-methylbutyrylamino)ethyl)benzoic acid;
[0179] (R)-4-(1-(3-methyl-2-((3-(methylsulfonyl)benzyl)oxy)butyrylamino)cyclopropyl)benzoic acid;
[0180] 4-((S)-1-((R)-2-((5-(difluoromethyl)pyridin-2-yl)methoxy)-3-methylbutyrylamino)ethyl)benzoic acid;
[0181] 4-((S)-1-((R)-2-((4-fluoro-3-(methylsulfonyl)benzyl)oxy)-3-methylbutyrylamino)ethyl)benzoic acid;
[0182] 2-Methyl-4-((S)-1-((R)-3-methyl-2-((4-(trifluoromethyl)benzyl)oxy)butyrylamino)ethyl)benzoic acid;
[0183] (R)-4-(1-(2-((3,4-difluorobenzyl)oxy)-3-methylbutyrylamino)cyclopropyl)benzoic acid;
[0184] 4-((S)-1-((R)-2-((3-hydroxybenzyl)oxy)-3-methylbutyrylamino)ethyl)benzoic acid;
[0185] 4-((S)-1-((R)-2-((3-cyclopropylbenzyl)oxy)-3-methylbutyrylamino)ethyl)benzoic acid;
[0186] 4-((S)-1-((R)-2-((3-(methoxymethyl)benzyl)oxy)-3-methylbutyrylamino)ethyl)benzoic acid;
[0187] 4-((S)-1-((R)-2-((4-hydroxybenzyl)oxy)-3-methylbutyrylamino)ethyl)benzoic acid;
[0188] (R)-N-((S)-1-(4-(1H-tetrazol-5-yl)phenyl)ethyl)-2-((4-fluorobenzyl)oxy)-3-methylbutanamide;
[0189] (R)-N-((S)-1-(4-(1H-tetrazol-5-yl)phenyl)ethyl)-3-methyl-2-((4-(trifluoromethyl)benzyl)oxy)butanamide;
[0190] 4-((S)-1-((R)-2-((3-(ethylsulfonyl)benzyl)oxy)-3-methylbutyrylamino)ethyl)benzoic acid;
[0191] 4-((S)-1-((R)-2-((3-(hydroxymethyl)benzyl)oxy)-3-methylbutyrylamino)ethyl)benzoic acid;
[0192] 4-((1S)-1-((2R)-2-(1-(4-fluorophenyl)ethoxy)-3-methylbutyrylamino)ethyl)benzoic acid;
[0193] 4-((1S)-1-(3-methyl-2-((4-(oxetan-3-yl)benzyl)oxy)butyrylamino)ethyl)benzoic acid;
[0194] 4-((1S)-1-(3-methyl-2-((3-(oxetan-3-yl)benzyl)oxy)butyrylamino)ethyl)benzoic acid;
[0195] (R)-4-(1-(2-((3-chlorobenzyl)oxy)-3-methylbutyrylamino)cyclopropyl)benzoic acid;
[0196] 4-((1S)-1-((2R)-3-methyl-2-(1-(4-(trifluoromethyl)phenyl)ethoxy)butyrylamino)ethyl)benzoic acid;
[0197] (R)-4-(1-(2-((3-(difluoromethoxy)benzyl)oxy)-3-methylbutyrylamino)cyclopropyl)benzoic acid;
[0198] 4-((S)-1-((R)-3-methyl-2-((4-(trifluoromethyl)benzyl)oxy)butyrylamino)ethyl)-N-(methylsulfonyl)benzamide;
[0199] (R)-4-(1-(2-((3-cyanobenzyl)oxy)-3-methylbutyrylamino)cyclopropyl)benzoic acid;
[0200] (R)-4-(1-(2-((2,2-difluorobenzo[d][1,3]dioxol-5-yl)methoxy)-3-methylbutyrylamino)cyclopropyl)benzoic acid;
[0201] (R)-4-(1-(2-((3-(ethylsulfonyl)benzyl)oxy)-3-methylbutyrylamino)cyclopropyl)benzoic acid;
[0202] (R)-4-(1-(2-((3-(difluoromethoxy)-4-fluorobenzyl)oxy)-3-methylbutyrylamino)cyclopropyl)benzoic acid;
[0203] (R)-4-(1-(3-methyl-2-((3-(trifluoromethoxy)benzyl)oxy)butyrylamino)cyclopropyl)benzoic acid;
[0204] (R)-4-((3-methyl-2-((4-(trifluoromethyl)benzyl)oxy)butyrylamino)methyl)benzoic acid;
[0205] (R)-4-(1-(2-((3-(methoxymethyl)benzyl)oxy)-3-methylbutyrylamino)cyclopropyl)benzoic acid;
[0206] (R)-4-(1-(2-((4-(difluoromethyl)-3-fluorobenzyl)oxy)-3-methylbutyrylamino)cyclopropyl)benzoic acid;
[0207] (R)-4-(1-(2-((4-(difluoromethyl)benzyl)oxy)-3-methylbutyrylamino)cyclopropyl)benzoic acid;
[0208] (R)-4-(1-(3-methyl-2-((4-(trifluoromethyl)benzyl)oxy)butyrylamino)cyclopropyl)-N-(methylsulfonyl)benzamide;
[0209] (R)-4-(2-(3-methyl-2-((4-(trifluoromethyl)benzyl)oxy)butyrylamino)propan-2-yl)benzoic acid;
[0210] (R)-4-(1-(2-((3-cyclopropylbenzyl)oxy)-3-methylbutyrylamino)cyclopropyl)benzoic acid;
[0211] 4-((S)-1-((R)-2-(imidazo[1,2-a]pyridin-7-ylmethoxy)-3-methylbutyrylamino)ethyl)benzoic acid;
[0212] (R)-4-(1-(2-((2-(difluoromethoxy)pyridin-4-yl)methoxy)-3-methylbutyrylamino)cyclopropyl)benzoic acid;
[0213] (R)-4-(1-(2-((4-(difluoromethoxy)pyridin-2-yl)methoxy)-3-methylbutyrylamino)cyclopropyl)benzoic acid;
[0214] (R)-N-(1-(4-(1H-tetrazol-5-yl)phenyl)cyclopropyl)-3-methyl-2-((4-(trifluoromethyl)benzyl)oxy)butanamide;
[0215] (R)-N-(1-(4-(1H-tetrazol-5-yl)phenyl)cyclopropyl)-2-((4-fluorobenzyl)oxy)-3-methylbutanamide;
[0216] (R)-N-(1-(4-(1H-tetrazol-5-yl)phenyl)cyclopropyl)-2-((3,4-difluorobenzyl)oxy)-3-methylbutanamide;
[0217] (R)-N-(1-(4-(1H-tetrazol-5-yl)phenyl)cyclopropyl)-2-((3-(difluoromethoxy)benzyl)oxy)-3-methylbutanamide;
[0218] (R)-4-(1-(3-methyl-2-((4-(trifluoromethyl)benzyl)oxy)butyrylamino)cyclobutyl)benzoic acid;
[0219] 4-((S)-1-((R)-2-((2-(difluoromethoxy)pyridin-4-yl)methoxy)-3-methylbutyrylamino)ethyl)benzoic acid;
[0220] (R)-4-(1-(3-methyl-2-((5-(trifluoromethyl)pyridin-2-yl)methoxy)butyrylamino)cyclopropyl)benzoic acid;
[0221] (R)-4-(1-(3-methyl-2-((6-(trifluoromethyl)pyridin-3-yl)methoxy)butyrylamino)cyclopropyl)benzoic acid;
[0222] 4-((S)-1-((R)-2-((4-(difluoromethoxy)pyridin-2-yl)methoxy)-3-methylbutyrylamino)ethyl)benzoic acid;
[0223] (R)-4-(1-(2-((3-chloro-4-fluorobenzyl)oxy)-3-methylbutyrylamino)cyclopropyl)benzoic acid;
[0224] 4-(1-((2R)-2-((4-chloro-5-fluorocyclohexa-1,3-dien-1-yl)methoxy)-3-methylbutyrylamino)cyclopropyl)benzoic acid;
[0225] (R)-2-((3-cyclopropylbenzyl)oxy)-N-(1-(4-(2,3-dihydro-1H-tetrazol-5-yl)phenyl)cyclopropyl)-3-methylbutanamide;
[0226] N-(Cyclopropylsulfonyl)-4-((S)-1-((R)-2-((4-fluorobenzyl)oxy)-3-methylbutyrylamino)ethyl)benzamide;
[0227] (R)-N-((S)-1-(4-(1H-tetrazol-5-yl)phenyl)ethyl)-2-((3-(difluoromethoxy)benzyl)oxy)-3-methylbutanamide;
[0228] (R)-N-((S)-1-(4-(1H-tetrazol-5-yl)phenyl)ethyl)-2-((3-cyclopropylbenzyl)oxy)-3-methylbutanamide;
[0229] (R)-4-(1-(2-((6-(difluoromethyl)pyridin-3-yl)methoxy)-3-methylbutyrylamino)cyclopropyl)benzoic acid;
[0230] 4-((S)-1-((R)-2-((3-cyclopropyl-4-fluorobenzyl)oxy)-3-methylbutyrylamino)ethyl)benzoic acid;
[0231] 4-(1-(3-methyl-2-((3-(oxetan-3-yl)benzyl)oxy)butyrylamino)cyclopropyl)benzoic acid;
[0232] (R)-4-(1-(2-((5-(difluoromethyl)pyridin-2-yl)methoxy)-3-methylbutyrylamino)cyclopropyl)benzoic acid;
[0233] (R)-4-(1-(2-((3-cyclopropyl-4-fluorobenzyl)oxy)-3-methylbutyrylamino)cyclopropyl)benzoic acid;
[0234] 4-((S)-1-((R)-2-((3-(cyclopropylsulfonyl)benzyl)oxy)-3-methylbutyrylamino)ethyl)benzoic acid;
[0235] (R)-4-(1-(2-((3-(cyclopropylsulfonyl)benzyl)oxy)-3-methylbutyrylamino)cyclopropyl)benzoic acid;
[0236] 4-((1S)-1-(2-cyclobutyl-2-((4-(trifluoromethyl)benzyl)oxy)acetylamino)ethyl)benzoic acid;
[0237] 4-(1-(2-cyclobutyl-2-((3-(methylsulfonyl)benzyl)oxy)acetylamino)cyclopropyl)benzoic acid;
[0238] 4-(1-(2-cyclobutyl-2-((4-(trifluoromethyl)benzyl)oxy)acetylamino)cyclopropyl)benzoic acid;
[0239] 4-(1-(2-cyclobutyl-2-((3,4-difluorobenzyl)oxy)acetylamino)cyclopropyl)benzoic acid;
[0240] 4-(1-(2-((3-chlorobenzyl)oxy)-2-cyclobutylacetylamino)cyclopropyl)benzoic acid;
[0241] 4-(1-(2-cyclobutyl-2-((3-(difluoromethoxy)benzyl)oxy)acetylamino)cyclopropyl)benzoic acid;
[0242] (S)-4-(1-(2-cyclobutyl-2-((3-(difluoromethoxy)benzyl)oxy)acetylamino)cyclopropyl)benzoic acid;
[0243] (R)-4-(1-(2-cyclobutyl-2-((3-(difluoromethoxy)benzyl)oxy)acetylamino)cyclopropyl)benzoic acid;
[0244] or a salt thereof.
[0245] Certain novel compounds of the present invention show particularly high activity as EP4 receptor antagonists.
[0246] Further embodiments of the present invention include the use of compounds of formula (1) as EP4 receptor antagonists. Such use may be in the treatment of abdominal aortic aneurysm (AAA), ankylosing spondylitis (AS), Alzheimer's disease (AD), atherosclerosis, cancers including epithelial cancers (GBD neoplasms of colon and rectum, lip and oral cavity, nasopharynx, other pharynx, gallbladder and bile duct, pancreas, non-melanoma skin, ovary, testis, kidney, bladder, thyroid, mesothelioma, esophagus, stomach, liver, larynx, trachea, bronchi and lung, breast, cervix, uterus, prostate), diabetic nephropathy, endometriosis, inflammatory bowel disease, migraine, multiple sclerosis (MS), osteoarthritis (OA) or rheumatoid arthritis.
[0247] definition
[0248] In this application, the following definitions apply unless indicated otherwise.
[0249] With respect to the use of any compound described herein, including those of formula (i), the term "treatment" is used to describe any form of intervention in which a compound is administered to a subject suffering from, or at risk of, or potentially at risk of the disease or disorder in question. Thus, the term "treatment" encompasses both preventative (prophylactic) treatment and treatment in which measurable symptoms or detectable symptoms of a disease or disorder are exhibited.
[0250] The term "therapeutically effective amount" (e.g., with respect to a treatment method for a disease or condition) refers to an amount of a compound that is effective to produce the desired therapeutic effect. For example, if the condition is pain, a therapeutically effective amount is an amount sufficient to provide a desired level of pain relief. A desired level of pain relief can be, for example, complete elimination of pain or a reduction in the severity of pain.
[0251] Unless otherwise indicated, the terms "alkyl", "alkoxy", "cycloalkyl", "phenyl", "pyridyl", "carbocycle", and "heterocycle" are all used in their conventional sense (e.g., as defined in the IUPAC Gold Book). "Optionally substituted" as applied to any group means that the group may be substituted, if desired, with one or more substituents, which may be the same or different.
[0252] In the above R 5 and R 6In the definition of, in the case of stating, one or two carbon atoms of alkyl group or cycloalkyl group but not all carbon atoms can be optionally replaced by heteroatoms selected from O and N. In the case where the group is a single carbon (C1) group, carbon cannot be replaced. It will be understood that when carbon atoms are replaced by heteroatoms, the heteroatom valence lower than carbon means that the atom ratio of the atom bonded to the heteroatom will be less than the atom bonded to the carbon atom that has been replaced. Therefore, for example, replacing the carbon atom (valence of 4) in the CH2 group by oxygen (valence of 2) will mean that the resulting molecule will contain two less hydrogen atoms, and replacing the carbon atom (valence of 4) in the CH2 group by nitrogen (valence of 3) will mean that the resulting molecule will contain one less hydrogen atom.
[0253] Examples of heteroatom replacements for carbon atoms include replacement of carbon atoms in a -CH2-CH2-CH2- chain with oxygen or sulfur to give an ether -CH2-O-CH2- or a thioether -CH2-S-CH2-, replacement of a carbon atom in a group CH2-C≡CH with nitrogen to give a nitrile (cyano) group CH2-C≡N, replacement of a carbon atom in a group -CH2-CH2-CH2- with C=O to give a ketone -CH2-C(O)-CH2-, replacement of a carbon atom in a group -CH2-CH=CH2 with C=O to give an aldehyde -CH2-C(O)H, replacement of a carbon atom in a group -CH2-CH2-CH3 with O to give an alcohol -CH2-CH2-CH2OH, replacement of a carbon atom in a group -CH2-CH2-CH3 with O to give an ether -CH 2-O-CH3, replacing carbon atoms in the group -CH2-CH2-CH3 with S to give thiols -CH2-CH2-CH2SH, replacing carbon atoms in the group -CH2-CH2-CH2- with S=O or SO2 to give sulfoxides -CH2-S(O)-CH2- or sulfones -CH2-S(O)2-CH2-, replacing carbon atoms in the -CH2-CH2-CH2- chain with C(O)NH to give amides -CH2-CH2-C(O)-NH-, replacing carbon atoms in the -CH2-CH2-CH2- chain with nitrogen to give amines -CH2-NH-CH2-, and replacing carbon atoms in the -CH2-CH2-CH2- chain with C(O)O to give esters (or carboxylic acids) -CH2-CH2-C(O)-O-. In each such replacement, at least one carbon atom in the alkyl group or cycloalkyl group must remain.
[0254] To the extent that any of the compounds described have chiral centers, the present invention extends to all optical isomers of such compounds, whether in the form of racemates or resolved enantiomers. However, the invention described herein relates to all crystalline forms, solvates and hydrates of any disclosed compound so prepared. To the extent that any of the compounds disclosed herein have acidic centers or basic centers such as carboxylic acid groups or amino groups, all salt forms of the compounds are included herein. In the case of pharmaceutical use, salts should be regarded as pharmaceutically acceptable salts.
[0255] Salts or pharmaceutically acceptable salts that may be mentioned include acid addition salts and base addition salts. Such salts can be formed by conventional means, for example, by reacting the free acid form or free base form of the compound with one or more equivalents of a suitable acid or base, optionally in a solvent or in a medium in which the salt is insoluble, followed by removal of the solvent or medium using standard techniques (e.g., in a vacuum, by freeze drying or by filtering). Salts can also be prepared, for example, using suitable ion exchange resins, by exchanging the counter ions of the compound in salt form with another counter ion.
[0256] Examples of pharmaceutically acceptable salts include acid addition salts derived from inorganic and organic acids, and salts derived from metals such as sodium, magnesium, potassium and calcium.
[0257] Examples of acid addition salts include acid addition salts formed with acetic acid, 2,2-dichloroacetic acid, adipic acid, alginic acid, arylsulfonic acids (e.g., benzenesulfonic acid, naphthalene-2-sulfonic acid, naphthalene-1,5-disulfonic acid and p-toluenesulfonic acid), ascorbic acid (e.g., L-ascorbic acid), L-aspartic acid, benzoic acid, 4-acetamidobenzoic acid, butyric acid, (+) camphoric acid, camphorsulfonic acid, (+)-(1S)-camphor-10-sulfonic acid, decanoic acid, hexanoic acid, octanoic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic acid, formic acid, fumaric acid , mucic acid, gentisic acid, glucoheptonic acid, gluconic acid (e.g., D-gluconic acid), glucuronic acid (e.g., D-glucuronic acid), glutamic acid (e.g., L-glutamic acid), α-ketoglutaric acid, glycolic acid, hippuric acid, hydrobromic acid, hydrochloric acid, hydroiodic acid, isethionic acid, lactic acid (e.g., (+)-L-lactic acid and (±)-DL-lactic acid), lactobionic acid, maleic acid, malic acid (e.g., (-)-L-malic acid), malonic acid, (±)-DL-mandelic acid, metaphosphoric acid, methanesulfonic acid, 1-hydroxy-2-naphthoic acid, nicotinic acid, nitric acid, oleic acid, orotic acid, oxalic acid, palmitic acid, pamoic acid (e.g., pamoic acid), acid), phosphoric acid, propionic acid, L-pyroglutamic acid, salicylic acid, 4-amino-salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tannic acid, tartaric acid (e.g., (+)-L-tartaric acid), thiocyanic acid, undecylenic acid, and valeric acid.
[0258] Also contemplated are any solvates of these compounds and their salts. Preferred solvates are solvates formed by incorporating molecules of a non-toxic pharmaceutically acceptable solvent (hereinafter referred to as a solvating solvent) into the solid state structure (e.g., crystal structure) of the compounds of the present invention. Examples of such solvents include water, alcohols (such as ethanol, isopropanol and butanol) and dimethyl sulfoxide. Solvates can be prepared by recrystallizing the compounds of the present invention with a solvent or a mixture of solvents containing a solvating solvent. Whether a solvate has been formed in any given case can be determined by subjecting the crystals of the compound to analysis using well-known techniques and standard techniques such as thermogravimetric analysis (TGA), differential scanning calorimetry (DSC) and X-ray crystallography.
[0259] The solvate can be a stoichiometric solvate or a non-stoichiometric solvate. A specific solvate can be a hydrate, and examples of hydrates include hemihydrates, monohydrates, and dihydrates. For a more detailed discussion of solvates and methods for preparing and characterizing them, see Bryn et al., Solid-State Chemistry of Drugs, Second Edition, published by SSCI, Inc of West Lafayette, IN, USA, 1999, ISBN 0-967-06710-3.
[0260] In the context of the present invention, the term "pharmaceutical composition" means a composition comprising an active agent and additionally comprising one or more pharmaceutically acceptable carriers. Depending on the nature of the mode of administration and the dosage form, the composition may also comprise ingredients selected from, for example, diluents, adjuvants, excipients, vehicles, preservatives, fillers, disintegrants, wetting agents, emulsifiers, suspending agents, sweeteners, flavoring agents, perfuming agents, antibacterial agents, antifungal agents, lubricants and dispersants. The composition may take, for example, the following forms: tablets; dragees; powders; elixirs; syrups; liquid products, including suspensions, sprays, inhalants, tablets, lozenges, emulsions, solutions, cachets, granules, capsules and suppositories; and liquid products for injection, including liposomal products.
[0261] The compounds of the invention may contain one or more isotopic substitutions, and reference to a particular element includes within its scope all isotopes of that element. For example, reference to hydrogen includes within its scope 1 H. 2 H(D) and 3 H(T). Similarly, references to carbon and oxygen include within their scope 12 C. 13 C and 14 C and16 O and 18 O. In a similar manner, unless the context indicates otherwise, reference to a particular functional group also includes isotopic variations within its scope. For example, reference to an alkyl group such as an ethyl group or an alkoxy group such as a methoxy group also covers variations in which one or more hydrogen atoms in the group are in the form of deuterium or tritium isotopes, for example, such as an ethyl group in which all five hydrogen atoms are in the form of deuterium isotopes (perdeuteroethyl group), or a methoxy group in which all three hydrogen atoms are in the form of deuterium isotopes (trideuteromethoxy group). Isotopes can be radioactive or non-radioactive.
[0262] The therapeutic dose may vary depending on the needs of the patient, the severity of the condition to be treated, and the compound employed. The determination of a dose suitable for a particular situation is within the skill of the art. Typically, treatment is initiated with a smaller dose that is less than the optimal dose of the compound. Thereafter, the dose is increased in small increments until the optimal effect under the circumstances is achieved. For convenience, the total daily dose may be divided and administered in batches during a day if desired.
[0263] Of course, the size (magnitude) of the effective dose of the compound will vary with the nature of the severity of the condition to be treated and with the specific compound and its route of administration. The selection of suitable dosage is within the ability of those of ordinary skill in the art, without excessive burden. Usually, the daily dosage range can be from about 10 μg to about 30 mg per kg of human body weight and non-human animal body weight, preferably from about 50 μg to about 30 mg per kg of human body weight and non-human animal body weight, for example, from about 50 μg to about 10 mg per kg of human body weight and non-human animal body weight, for example, from about 100 μg to about 30 mg per kg of human body weight and non-human animal body weight, for example, from about 100 μg to about 10 mg per kg of human body weight and non-human animal body weight, and most preferably from about 100 μg to about 1 mg per kg of human body weight and non-human animal body weight.
[0264] Pharmaceutical preparations
[0265] While it is possible for the active compound to be administered alone, it is preferable to present it as a pharmaceutical composition (eg, formulation).
[0266] Therefore, in another embodiment of the present invention, there is provided a pharmaceutical composition comprising at least one compound of formula (1) as defined above together with at least one pharmaceutically acceptable excipient.
[0267] The composition may be a tablet composition. The composition may be a capsule composition.
[0268] Pharmaceutically acceptable excipients can be selected from, for example, carriers (e.g., solid carriers, liquid carriers, or semisolid carriers), adjuvants, diluents (e.g., solid diluents such as fillers or bulking agents; and liquid diluents such as solvents and co-solvents), granulating agents, binders, flow aids, coating agents, release controlling agents (e.g., release-delaying polymers or waxes or release-retarding polymers or waxes), binding agents, disintegrants, buffers, lubricants, preservatives, antifungal and antibacterial agents, antioxidants, buffers, tonicity modifiers, thickeners, flavoring agents, sweeteners, pigments, plasticizers, taste-masking agents, stabilizers, or any other excipients conventionally used in pharmaceutical compositions.
[0269] The term "pharmaceutically acceptable" as used herein means compounds, materials, compositions and / or dosage forms that are suitable for use in contact with the tissues of subjects (e.g., human subjects) without excessive toxicity, irritation, allergic response or other problems or complications, commensurate with a reasonable benefit / risk ratio, within the scope of sound medical judgment. Each excipient must also be "acceptable" in the sense of being compatible with the other ingredients of the formulation.
[0270] Pharmaceutical compositions comprising compounds of formula (1) can be formulated according to known techniques, see, for example, Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, PA, USA. The pharmaceutical compositions can be in any form suitable for oral, parenteral, topical, intranasal, intrabronchial, sublingual, ocular, otic, rectal, intravaginal or transdermal administration.
[0271] Suitable pharmaceutical dosage forms for oral administration include tablets (coated or uncoated), capsules (hard or soft shell), caplets, pills, lozenges, syrups, solutions, powders, granules, elixirs and suspensions, sublingual tablets, wafers, or patches such as a buccal patch.
[0272] Tablet compositions may include a unit dose of active compound together with an inert diluent or carrier, such as a sugar or sugar alcohol, e.g., lactose, sucrose, sorbitol, or mannitol; and / or a non-sugar derived diluent, such as sodium carbonate, calcium phosphate, calcium carbonate, or cellulose or a derivative thereof, such as microcrystalline cellulose (MCC), methylcellulose, ethylcellulose, hydroxypropylmethylcellulose, and starch such as corn starch. Tablets may also include standard ingredients such as: a binder and a granulating agent, such as polyvinylpyrrolidone; a disintegrant (e.g., a swellable cross-linked polymer, such as cross-linked carboxymethylcellulose); a lubricant (e.g., a stearate); a preservative (e.g., a paraben); an antioxidant (e.g., BHT); a buffer (e.g., a phosphate buffer or a citrate buffer); and an effervescent agent, such as a citrate / bicarbonate mixture. Such excipients are well known and need not be discussed in detail herein.
[0273] Tablets may be designed to release the drug upon contact with gastric fluid (immediate release tablets) or to release the drug in a controlled manner over an extended period of time or in a specific area of the GI tract (controlled release tablets).
[0274] The pharmaceutical composition generally comprises from about 1% (w / w) to about 95% (preferably % (w / w)) of active ingredient and from 99% (w / w) to 5% (w / w) of a pharmaceutically acceptable excipient (e.g. as defined above) or a combination of such excipients. Preferably, the composition comprises from about 20% (w / w) to about 90% (w / w) of active ingredient and from 80% (w / w) to 10% of a pharmaceutically acceptable excipient or a combination of excipients. The pharmaceutical composition comprises from about 1% to about 95%, preferably from about 20% to about 90% of active ingredient. The pharmaceutical composition according to the present invention can be, for example, in unit dose form, such as in the form of ampoules, vials, suppositories, prefilled syringes, dragees, powders, tablets or capsules.
[0275] Tablets and capsules may contain, for example, 0%-20% disintegrants, 0%-5% lubricants, 0%-5% glidants, and / or 0%-99% (w / w) fillers or bulking agents (depending on the drug dose). They may also contain 0%-10% (w / w) polymer binders, 0%-5% (w / w) antioxidants, 0%-5% (w / w) pigments. In addition, slow-release tablets will typically contain 0%-99% (w / w) controlled-release (e.g., delayed-release) polymers (depending on the dose). The film coating of a tablet or capsule typically contains 0%-10% (w / w) polymers, 0%-3% (w / w) pigments, and / or 0%-2% (w / w) plasticizers.
[0276] Parenteral formulations typically contain 0%-20% (w / w) buffer, 0%-50% (w / w) cosolvent and / or 0%-99% (w / w) water for injection (WFI) (depending on dose and whether lyophilized). Formulations for intramuscular depots may also contain 0%-99% (w / w) oil.
[0277] Pharmaceutical formulations may be provided to patients in "patient packs" containing an entire course of treatment within a single package, usually a blister pack.
[0278] The compound of formula (1) will generally be presented in a unit dosage form, and therefore will generally contain enough compound to provide the desired level of biological activity. For example, the formulation may contain from 1 nanogram to 2 grams of active ingredient, for example from 1 nanogram to 2 milligrams of active ingredient. Within these ranges, a specific subrange of the compound is 0.1 milligram to 2 grams of active ingredient (more generally from 10 milligrams to 1 gram, for example 50 milligrams to 500 milligrams), or 1 microgram to 20 milligrams (e.g. 1 microgram to 10 milligrams, for example 0.1 milligram to 2 milligrams of active ingredient).
[0279] For oral compositions, unit dosage forms may contain from 1 mg to 2 g, more typically 10 mg to 1 g, for example 50 mg to 1 g, for example 100 mg to 1 g, of active compound.
[0280] The active compound will be administered to a patient (eg, a human patient or an animal patient) in need thereof in an amount sufficient to achieve the desired therapeutic effect (effective amount). The precise amount of compound administered can be determined by the supervising physician according to standard procedures. Example
[0281] The invention will now be illustrated, without however being limited, by reference to the following examples.
[0282] Example 1 to Example 101
[0283] The compounds of Examples 1 to 101 shown in Table 1 below have been prepared. In some cases, the compounds were obtained as mixtures of stereoisomers, and Examples 3, 6, 46, 47, 51, 92, 95, 96, 97, 98 and 99 refer to such mixtures as indicated in Tables 1 and 2. In other cases, the compounds were obtained as single isomers with or without specified stereochemistry. Examples 17, 18, 48, 49, 86, 87, 93 and 94 refer to single isomers with unspecified stereochemistry as indicated in Table 1.
[0284] Table 1 - Example compounds
[0285]
[0286]
[0287]
[0288]
[0289]
[0290]
[0291]
[0292]
[0293] Method for preparing the compound of formula (1)
[0294] The compounds of formula (1) can be prepared according to synthetic methods well known to the skilled person. Also provided is a process for preparing the compounds as defined in formula (1) above.
[0295] Solution 1
[0296]
[0297] Compounds of formula (1) can be prepared as outlined in Scheme 1. Amide bond formation between an acid of formula G1 and an amine of formula G2 is typically carried out in the presence of a suitable coupling agent such as HATU and a base such as N,N-diisopropylethylamine in a solvent such as MeCN or dichloromethane to produce the desired amide of formula G3. Alcohol G3 is alkylated with an alkylating agent of formula G4 (wherein LG1 represents a suitable leaving group, typically bromine). Typically, the alkylation reaction is carried out in the presence of a base such as NaH and in a solvent such as THF at a temperature ranging from 0°C to room temperature to provide a compound of formula (1). Alternatively, compounds of formula (1) can be prepared by displacing a suitable alkylating agent G4 (wherein LG2 represents a suitable leaving group, typically mesylate) with an alcohol of formula G5. Typical conditions include the use of a base such as KOtBu and in a solvent such as THF at a temperature ranging from 0°C to 70°C. Compounds of formula G4 can be prepared by activation of the corresponding alcohol of formula G3 (wherein LG2 represents a suitable leaving group, typically a mesylate). Typically, the reaction is carried out in the presence of a base such as triethylamine and in a solvent such as dichloromethane at a temperature in the range of from 0°C to room temperature to provide compounds of formula G4.
[0298] In compounds where A is a protected carboxylic acid group (wherein PG represents a suitable acid protecting group such as a methyl ester), further deprotection may be performed using conditions related to the nature of the protecting group. Typically, hydrolysis of the methyl ester function in the presence of a nucleophilic base such as lithium hydroxide in a solvent such as MeOH or THF provides compounds of formula (7).
[0299] The skilled person will appreciate that the reaction steps depicted in Scheme 1 can be combined in different ways as desired to successfully prepare the desired compounds of formula (1) and formula (7). This may include additional steps, such as functional group modification, protection and / or deprotection steps in the overall synthetic sequence. For example, compounds of formula (7) can be prepared as shown in Scheme 2.
[0300] The alcohol of formula G6 (wherein PG2 represents a suitable acid protecting group such as methyl ester) is alkylated with an alkylating agent of formula G4 (wherein LG represents a suitable leaving group, typically bromine). Typically, the alkylation reaction is carried out in the presence of a base such as NaH and in a solvent such as THF at a temperature ranging from 0°C to room temperature to provide an ether of formula G7. The resulting ester can be deprotected using conditions related to the properties of the protecting group PG2, typically hydrolyzing the methyl ester functional group in a solvent such as THF in the presence of a nucleophilic base such as lithium hydroxide to provide an acid of formula G8. The amide bond formation reaction between the acid of formula G8 and the amine of formula G2 in a solvent such as DCM or DMF in the presence of an amide coupling agent such as HATU or EDCI and a base such as triethylamine provides a compound of formula (1). In compounds where A is a protected carboxylic acid group, deprotection can be achieved as described in Scheme 1.
[0301] Solution 2
[0302]
[0303] It should be understood that the above schemes and procedures are not meant to be limiting in any way. In fact, the above schemes and procedures can also be used to prepare compounds of the present invention, wherein, for example, A is a carboxylic acid isostere group. Methods and protecting groups suitable for "A groups" are well known to those skilled in the art, for example, a trityl group can be used to protect a tetrazole group. In addition, a compound of formula 1 can be converted into another compound of the present invention by methods well known to the technician. Examples of synthetic procedures for converting one functional group into another are described in standard textbooks, such as March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 7th Edition, Michael B. Smith, John Wiley, 2013, (ISBN: 978-0-470-46259-1), Organic Syntheses, Online Edition, www.orgsyn.org, (ISSN 2333-3553), and Fiesers' Reagents for Organic Synthesis, Volumes 1-17, John Wiley, edited by Mary Fieser (ISBN: 0-471-58283-2).
[0304] In many of the reactions described above, it may be necessary to protect one or more groups to prevent the reaction from occurring at undesirable locations on the molecule. Examples of protecting groups and methods of protecting and deprotecting functional groups can be found in Greene's Protective Groups in Organic Synthesis, Fifth Edition, Editor: Peter GMWuts, John Wiley, 2014, (ISBN: 9781118057483).
[0305] The compounds prepared by the aforementioned methods can be isolated and purified by any of a variety of methods well known to those skilled in the art, and examples of such methods include recrystallization and chromatographic techniques, such as column chromatography under normal phase conditions or reverse phase conditions (e.g. flash chromatography), HPLC and SFC.
[0306] General Procedure
[0307] Where preparative routes are not included, the relevant intermediates are commercially available. Commercial reagents were used without further purification. Final compounds and intermediates were named using ChemDraw Professional, version 17.0.0.206 (121). Room temperature (RT) refers to approximately 20°C-27°C. Recorded at 400 MHz or 500 MHz on Bruker, Varian or Jeol instruments 1 H NMR spectra. Chemical shift values are expressed in parts per million (ppm), i.e. (δ)-values relative to the following solvents: chloroform-d=7.26 ppm, DMSO-d6=2.50 ppm, methanol-d4=3.31 ppm. The following abbreviations are used for the multiplicity of NMR signals: s=singlet, br=broad, d=doublet, t=triplet, q=quartet, m=multiplet. Coupling constants are listed as J values measured in Hz. NMR and mass spectrometry results are corrected to take background peaks into account. Chromatography refers to the use of 60-120 mesh or 40 μm-633 μm, Column chromatography on silica gel and performed under nitrogen pressure (flash chromatography). Microwave mediated reactions were performed in a Biotage Initiator or a CEM Discover microwave reactor.
[0308] LC / MS analysis
[0309] LC / MS analysis of the compounds was performed under electrospray conditions using the instrumentation and methods given below:
[0310] LC / MS Method A and LC / MS Method B
[0311] Instrument: Agilent 1260 Infinity LC with diode array detector and Agilent MS 6120; Column: Phenomenex Gemini-NX, C-18, 3 micron, 30×2 mm; Method A gradient [time (min) / solvent B in A (%)]: 0.00 / 2, 0.1 / 2, 8.4 / 95, 10.0 / 95, 10.1 / 2, 12.0 / 2; Method B gradient [time (min) / solvent B in A (%)]: 0.00 / 5, 2.0 / 95, 2.5 / 95, 2.6 / 5, 3.0 / 5; Solvents: Solvent A = water (2.5 L) with 28% aqueous ammonia solution (2.5 mL); Solvent B: acetonitrile (2.5 L) with water (125 mL) and 28% aqueous ammonia solution (2.5 mL); Column temperature: 40° C.; Flow rate: 1.5 mL / min.
[0312] LC / MS Method C
[0313] Instrument: HP 1100 with G1315A DAD, Waters Micromass ZQ; Column: Phenomenex Gemini-NX C-18, 3 microns, 2.0×30 mm; Gradient [time (min) / solvent B in A (%)]: 0.00 / 2, 0.01 / 2, 8.40 / 95, 10.00 / 95; Solvent: Solvent A = 2.5 L H2O + 2.5 mL of 28% ammonia solution in H2O; Solvent B = 2.5 L MeCN + 135 mL H2O + 2.5 mL of 28% ammonia solution in H2O. Injection volume 1 μL; UV detection 230 nm to 400 nm; Mass detection 130 AMU to 800 AMU; Column temperature 45° C.; Flow rate 1.5 mL / min.
[0314] LC / MS Method D and LC / MS Method E
[0315] Instrument: Aquity H-Class with PDA detector and QDa mass detector; Column: C-18, 1.6 micron, 50×2.1 mm; Method D gradient [time (min) / solvent B in A (%)]: 0.00 / 3, 0.20 / 3, 2.70 / 98, 3.00 / 100, 3.50 / 100, 3.51 / 3, 4.00 / 4; Method E gradient [time (min) / solvent B in A (%)]: 0.00 / 5, 0.20 / 5, 1.80 / 98, 2.00 / 100, 2.50 / 100, 2.15 / 5, 3.00 / 5; Solvents: Solvent A = 0.1% formic acid in water; Solvent B = 0.1% formic acid in acetonitrile: water (90:10); Column temperature: 35°C; Flow rate: 1 mL / min.
[0316] LC / MS Method F
[0317] Instrument: Agilent Infinity II G6125C LCMS; Column: C-18, 3.5 μm, 50×4.6 mm; Gradient [time (min) / solvent B in A (%)]: 0.00 / 8, 0.75 / 8, 3.00 / 70, 3.70 / 95, 4.20 / 100, 5.20 / 100, 5.21 / 8, 7.00 / 8; Solvent: Solvent A = 5 mM aqueous ammonium bicarbonate; Solvent B = methanol; Column temperature: 35°C; Flow rate: 0.9 mL / min.
[0318] LC / MS Method G
[0319] Instrument: Agilent Infinity II G6125C LCMS; Column: C-18, 3.5 μm, 50×4.6 mm; Gradient [time (min) / solvent B in A (%)]: 0.00 / 5, 1.00 / 5, 3.00 / 60, 4.50 / 90, 7.00 / 100, 8.00 / 100, 8.01 / 5, 10.0 / 5; Solvent: Solvent A = 0.1% ammonia in water; Solvent B = acetonitrile; Column temperature: 35° C.; Flow rate: 1.0 mL / min.
[0320] LC / MS Method H
[0321] Instrument: Waters Alliance 2690 with 996PDA detector and Micromass ZQ; Column: C-18, 3.5 micron, 150×4.6 mm; Gradient [time (min) / solvent B in A (%)]: 0.00 / 10, 7.00 / 90, 9.00 / 100, 14.0 / 100, 14.01 / 10, 17.00 / 10; Solvent: Solvent A = 5 mM aqueous ammonium acetate and 0.1% formic acid; Solvent B = methanol; Column temperature: 35° C.; Flow rate: 1.0 mL / min.
[0322] LC / MS Method I
[0323] Instrument: Waters Aquity UPLC Binary equipped with PDA detector and SQ detector; Column: Waters Sunfire C18, 3.5 micron, 150×4.6 mm; Isocratic [time (min) / solvent B in A (%)]: 0.00 / 70, 20.00 / 70; Solvent: Solvent A = 5 mM aqueous ammonium acetate + 0.1% formic acid; Solvent B = methanol; Column temperature: 35°C; Flow rate: 1 mL / min.
[0324] Analytical SFC Method J
[0325] Instrument: Waters Acquity UPC2 with Masslynx software, PDA detector and QDa mass detector; Column: Phenomenex Lux Amylose-1, 3 μm, 50×2 mm; Wavelength: detection from 210 nm to 400 nm; Gradient [time (min) / solvent B in A (%)]: 0.00 / 3, 3.00 / 50, 4.00 / 50, 5.00 / 3; Solvent: Solvent A=CO2; Solvent B=IPA; Column temperature: 45°C; Flow rate: 1.5 mL / min.
[0326] Analytical Chiral HPLC Method K
[0327] Instrument: Shimadzu LC 20AD; Column: CHIRALPAK IG, 5 μm, 250×4.6 mm; Isocratic [time (min) / solvent B in A (%)]: 0.00 / 20, 30.00 / 20; Solvent: Solvent A = n-heptane; Solvent B = 2-propanol: ACN (70:30); Column temperature: RT; Flow rate: 1 mL / min.
[0328] Abbreviations used in this document
[0329] aq water
[0330] Bn Benzyl
[0331] DCM Dichloromethane
[0332] DMA Dimethylacetamide
[0333] DMF Dimethylformamide
[0334] dppf 1,1′-bis(diphenylphosphino)ferrocene
[0335] EDCI 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide
[0336] EtOAc Ethyl acetate
[0337] HATU 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate
[0338] HCl
[0339] HOBt Hydroxybenzotriazole
[0340] HPLC High Performance Liquid Chromatography
[0341] h / hr hour
[0342] hrs hours
[0343] IPA Isopropyl Alcohol
[0344] LC / MS Liquid chromatography / mass spectrometry
[0345] LiOH Lithium Hydroxide
[0346] M molar concentration
[0347] MeCN Acetonitrile
[0348] MeOH Methanol
[0349] Min Minutes
[0350] MTBE Methyl tert-butyl ether
[0351] N Normal
[0352] NaOH Sodium hydroxide
[0353] NaH Sodium hydride
[0354] prep HPLC Preparative High Performance Liquid Chromatography
[0355] RM reaction mixture
[0356] RT Room temperature
[0357] sat saturated
[0358] THF Tetrahydrofuran
[0359] UPLC Ultra-Performance Liquid Chromatography
[0360] V Volume
[0361] General synthetic procedures used in the examples
[0362] Route A
[0363] Procedure for the Preparation of Example 1, 4-((S)-1-((R)-3-methyl-2-((4-(trifluoromethyl)benzyl)oxy)butyrylamino)ethyl)benzoic acid
[0364]
[0365] Step (i): To an ice-cold solution of intermediate 1,4-((S)-1-((R)-2-hydroxy-3-methylbutyrylamino)ethyl)benzoate (11.3 g, 40.6 mmol) and potassium tert-butoxide (5.01 g, 44.7 mmol) in DMF (100 mL) was added 4-(trifluoromethyl)benzyl bromide (10.7 g, 44.7 mmol). The mixture was heated to room temperature and stirred for 6 hours before being partitioned between EtOAc and water. The organics were separated, washed with brine (×2), dried over MgSO4 and concentrated. The crude material was purified by flash column chromatography (normal phase, silica) under a gradient of EtOAc (0% to 50%) in isohexane to afford methyl 4-[(1S)-1-[[(2R)-3-methyl-2-[[4-(trifluoromethyl)phenyl]methoxy]butanoyl]amino]ethyl]benzoate (8.93 g, 20.4 mmol, 50% yield) as a white solid. (LC / MS Method B): m / z 438 [M+H] + (ES+ ), UV activity at 1.75 min.
[0366] Step (ii): To a solution of methyl 4-[(1S)-1-[[(2R)-3-methyl-2-[[4-(trifluoromethyl)phenyl]methoxy]butyryl]amino]ethyl]benzoate (7.44 g, 17.0 mmol) in water (28 mL) and methanol (15 mL) was added sodium hydroxide (3.40 g, 85.0 mmol) and the reaction mixture was heated to 70° C. for 5 hours. The mixture was cooled to room temperature and partitioned between ethyl acetate and 1M HCl. The organics were separated, dried and concentrated via passing through a hydrophobic frit. The crude material was triturated from diethyl ether and then recrystallized from a minimum amount of boiling isopropanol to provide Example 1, 4-((S)-1-((R)-3-methyl-2-((4-(trifluoromethyl)benzyl)oxy)butyrylamino)ethyl)benzoic acid (3.12 g, 7.4 mmol, 43.3% yield) as a white solid. The data are available in Table 2.
[0367] Route B
[0368] Procedure for the Preparation of Example 2, (R)-4-(1-(3-methyl-2-((4-(trifluoromethyl)benzyl)oxy)butyrylamino)cyclopropyl)benzoic acid
[0369]
[0370] Step (i): To an ice-cold mixture of intermediate 5 (R) -methyl 4- (1- (2-hydroxy-3-methylbutyrylamino) cyclopropyl) benzoate (212 mg, 0.73 mmol) in THF (3.6 ml) was added NaH (60% dispersion in mineral oil) (32 mg, 0.8 mmol), and the reaction mixture was stirred at room temperature for 10 minutes before adding intermediate 31 1- (bromomethyl) -4- (trifluoromethyl) benzene (192 mg, 0.8 mmol). The reaction was stirred at room temperature for 18 hours, then partitioned between water and EtOAc, the organics separated, washed with brine, dried (hydrophobic frit) and concentrated. The crude material was purified by flash column chromatography (normal phase) [gradient 0% - 45% EtOAc in isohexane] to give (R)-methyl 4-(1-(3-methyl-2-((4-(trifluoromethyl)benzyl)oxy)butyrylamino)cyclopropyl)benzoate (76 mg, 0.17 mmol, 23% yield) as an orange solid. LC / MS (Method C): m / z 450 [M+H] + , 1.73min.
[0371] Step (ii): (R)-4-(1-(3-methyl-2-((4-(trifluoromethyl)benzyl)oxy)butyrylamino)cyclopropyl)benzoic acid methyl ester (76 mg, 0.17 mmol) was suspended in 1,4-dioxane (0.4 mL) and water (0.4 mL), and lithium hydroxide monohydrate (28 mg, 0.68 mmol) was added. The reaction mixture was stirred at room temperature for 18 hours and then concentrated in vacuo. The crude material was purified by flash column chromatography (reverse phase) [gradient 10%-45% MeOH and 0.2% 28% NH4OH (aqueous) solution in water]. Example 2 (R)-4-(1-(3-methyl-2-((4-(trifluoromethyl)benzyl)oxy)butyrylamino)cyclopropyl)benzoic acid (36 mg, 0.08 mmol, 49%) was given as a white solid. Data are available in Table 2.
[0372] Alternative route of Example 2
[0373]
[0374] Step (i): at 0 ° C, R-2-hydroxy-3-methyl-butyric acid methyl ester (25g, 1.0 equivalent) in dry THF (10V) is placed in a flask. Then tetrabutylammonium iodide (0.1 equivalent) and intermediate 311-(bromomethyl)-4-(trifluoromethyl) benzene (44g, 1.0 equivalent) are added, RM is stirred for 15min, then NaH (1.5 equivalents) is added in batches, wherein the temperature is always maintained at 0 ° C. The reaction mixture is stirred for 1 hour at 0 ° C, and then RM is stirred at room temperature for 4 hours. After the reaction is completed, the reaction mixture is quenched with ice-cold water (10V), and the product is extracted with MTBE (3V×3), and the extracts are combined and evaporated under vacuum to provide a crude product of 40g. The crude compound was purified by column chromatography using 60-120 mesh silica gel, and the product was eluted in 1%-2% ethyl acetate and hexane system to provide 25 g of (R)-methyl 3-methyl-2-((4-(trifluoromethyl)benzyl)oxy)butanoate as a viscous liquid.
[0375] Step (ii): (R)-3-methyl-2-((4-(trifluoromethyl)benzyl)oxy)butanoic acid methyl ester (75 g, 1.0 eq.) in THF (3 V) was treated with LiOH (1.5 eq.) and water (1.5 V) at room temperature, and then stirred at 80 ° C for 4 hours. After the reaction was completed, THF was evaporated under vacuum, and the obtained residue was placed in water (5 V) and washed with MTBE (5 V). The aqueous layer was then acidified with 1N aqueous HCl (pH ~ 2). The product was then extracted with DCM (20 V × 2). The combined organic layers were evaporated under vacuum to obtain (R)-3-methyl-2-((4-(trifluoromethyl)benzyl)oxy)butanoic acid (62 g). The compound was used in the next step without any further purification.
[0376] Step (iii): At 0°C, (R)-3-methyl-2-((4-(trifluoromethyl)benzyl)oxy)butanoic acid (62 g, 1.0 eq.) in DMF (10 V) was placed in a flask followed by the addition of HATU (1.5 eq.), methyl 4-(1-aminocyclopropyl)benzoate (1.0 eq.) and DIPEA (3.0 eq.) at the same temperature. The reaction mixture was then allowed to heat to room temperature with continued stirring. After the reaction was complete, the reaction mixture was poured into water (10 V). The solid obtained was filtered, washed with cooling water (2 V) and dried under vacuum to give 105 g of a crude product. The crude compound was purified by column chromatography using 60-120 mesh silica gel, and the product was eluted in 10%-15% ethyl acetate and hexane system to provide (R)-methyl 4-(1-(3-methyl-2-((4-(trifluoromethyl)benzyl)oxy)butyrylamino)cyclopropyl)benzoate 58 g as a viscous liquid.
[0377] Step (iv): (R)-4-(1-(3-methyl-2-((4-(trifluoromethyl)benzyl)oxy)butyrylamino)cyclopropyl)benzoic acid methyl ester (58 g, 1.0 eq.) in THF (3 V) and water (1.5 V) was placed in a flask. The reaction mixture was cooled to 0°C-5°C, followed by addition of lithium hydroxide monohydrate (3.0 eq.) in portions at the same temperature over a period of 30 min. The reaction mixture was then heated to 80°C over a period of 30 min, and further stirred at 80°C for 4 hours. After completion of the reaction, the solvent was evaporated under vacuum. Water (5 V) was then added to the reaction mixture. The aqueous layer was washed with MTBE (5 V). The aqueous layer was then acidified with 1 N aqueous HCl (pH: 2 to 3), and the product was extracted in ethyl acetate (20 V×3). The combined organic layers were washed with water and evaporated under vacuum to give Example 2 (R)-4-(1-(3-methyl-2-((4-(trifluoromethyl)benzyl)oxy)butyrylamino)cyclopropyl)benzoic acid (43 g) as an off-white solid.
[0378] The material (79g) of other purification-this material and from other batches is further purified by being dissolved in heptane (10V) and being heated to 80 ℃, adding IPA (3V) at the same temperature subsequently.Then allow the mixture to cool to room temperature and stir for 30min.The solid obtained is filtered, washed with normal heptane (3V) and dried under vacuum (this is repeated twice).The product material (85g) merged is suspended in normal heptane (425mL, 5V) and stirred for 30min at room temperature.The solid is filtered, washed with normal heptane (2V) and dried under vacuum, to provide embodiment 2 (R)-4-(1-(3-methyl-2-((4-(trifluoromethyl) benzyl) oxygen base) butyrylamino) cyclopropyl) benzoic acid (82g).Data are available in table 2.
[0379] Route C
[0380] Procedure for the Preparation of Example 5, 4-((S)-1-((R)-2-((4-fluorobenzyl)oxy)-3-methylbutyrylamino)ethyl)benzoic acid
[0381]
[0382] Step (i): Under nitrogen atmosphere at 0 ℃, to NaH (60% in mineral oil) (0.071g, 1.77mmol) suspension in DMF (5mL) add intermediate 1,4-((S)-1-((R)-2-hydroxy-3-methylbutyrylamino)ethyl)methyl benzoate (0.45g, 1.61mmol). The mixture is stirred at the same temperature for 10 minutes, and then 1-(bromomethyl)-4-fluorobenzene (0.36g, 1.93mmol) is added. The mixture is heated to room temperature and stirred for 3 hours, and then the mixture is distributed between EtOAc and water. The organic matter is separated, and the water layer is further extracted with EtOAc (×2). The combined organic matter is dried over Na2SO4 and concentrated. The residue was purified by flash column chromatography (reverse phase, C18) under a gradient of MeCN (0%-62%) in water to afford methyl 4-((S)-1-((R)-2-((4-fluorobenzyl)oxy)-3-methylbutyrylamino)ethyl)benzoate (0.38 g, 0.99 mmol, 61% yield) as a white solid. (LC / MS Method D): m / z 388 [M+H] + (ES + ), UV activity at 2.67 min.
[0383] Step (ii): To a solution of methyl 4-((S)-1-((R)-2-((4-fluorobenzyl)oxy)-3-methylbutyrylamino)ethyl)benzoate (0.38 g, 0.98 mmol) in 1,4-dioxane (4 mL) and water (2 mL) was added lithium hydroxide monohydrate (0.21 g, 4.90 mmol). The mixture was stirred at room temperature for 5 hours, after which the mixture was acidified to pH 4 with glacial acetic acid and concentrated under reduced pressure. The residue was purified by flash column chromatography (reverse phase, C18) under a gradient of MeCN (0%-50%) in water to provide Example 5, 4-((S)-1-((R)-2-((4-fluorobenzyl)oxy)-3-methylbutyrylamino)ethyl)benzoic acid (0.28 g, 0.75 mmol, 76%) as an off-white solid. The data are available in Table 2.
[0384] Route D
[0385] Procedure for the Preparation of Example 6, 4-((1S)-1-(2-((4-methoxybenzyl)oxy)-3-methylbutyrylamino)ethyl)benzoic acid, mixture of diastereomers
[0386]
[0387] At 0 ℃, potassium tert-butoxide was added to a solution of (4-methoxyphenyl)methanol (0.20 g, 1.47 mmol) in THF (3.5 mL), and the mixture was stirred at the same temperature for 20 minutes. Intermediate 3, 4-((1S)-1-(3-methyl-2-((methylsulfonyl)oxy)butyrylamino)ethyl)methyl benzoate (0.35 g, 0.98 mmol) was added, and the mixture was stirred at 80 ℃ for 4 hours, after which the mixture was cooled to room temperature and distributed between EtOAc and water. The aqueous layer was separated, acidified to pH 1 with 1N HCl and extracted with EtOAc (×2). The combined organics were dried over Na2SO4 and concentrated. Note that partial ester hydrolysis occurs in the reaction. The residue was purified by flash column chromatography (reverse phase, C18) under a gradient of MeCN (0%-36%) in water to provide Example 6, 4-((1S)-1-(2-((4-methoxybenzyl)oxy)-3-methylbutyrylamino)ethyl)benzoic acid (0.13 g, 0.33 mmol, 34% yield) as a white solid. The data are available in Table 2.
[0388] Route E
[0389] Procedure for the Preparation of Example 11, 4-((S)-1-((R)-2-((4-chlorobenzyl)oxy)-3-methylbutyrylamino)ethyl)benzoic acid
[0390]
[0391] Step (i): Under nitrogen atmosphere at 0 ℃, to NaH (~60% in mineral oil) (0.05g, 1.34mmol) suspension in DMF (2mL) add intermediate 1,4-((S)-1-((R)-2-hydroxy-3-methylbutyrylamino)ethyl)methyl benzoate (0.25g, 0.89mmol). The mixture is stirred at the same temperature for 15 minutes, and then 1-(bromomethyl)-4-chlorobenzene (0.27g, 1.34mmol) is added. The mixture is heated to room temperature and stirred for 1 hour, and then the mixture is distributed between EtOAc and water. The organic matter is separated, and the water layer is further extracted with EtOAc (×2). The combined organic matter is dried over Na2SO4 and concentrated. The residue was purified by flash column chromatography (reverse phase, C18) under a gradient of MeCN (0%-90%) in water to afford methyl 4-((S)-1-((R)-2-((4-chlorobenzyl)oxy)-3-methylbutyrylamino)ethyl)benzoate (0.143 g, 0.35 mmol, 40% yield) as a viscous liquid. (LC / MS Method E): m / z 404 [M+H] + (ES+ ), UV activity at 1.91 min.
[0392] Step (ii): To a solution of methyl 4-((S)-1-((R)-2-((4-chlorobenzyl)oxy)-3-methylbutyrylamino)ethyl)benzoate (0.14 g, 0.35 mmol) in 1,4-dioxane (2 mL) and water (1 mL) was added lithium hydroxide monohydrate (70 mg, 1.77 mmol). The mixture was stirred at room temperature for 3 hours, after which the mixture was acidified to pH 4 with glacial acetic acid and concentrated under reduced pressure. The residue was purified by flash column chromatography (reverse phase, C18) under a gradient of MeCN (0%-56%) in water to provide Example 11, 4-((S)-1-((R)-2-((4-chlorobenzyl)oxy)-3-methylbutyrylamino)ethyl)benzoic acid (100 mg, 0.26 mmol, 74% yield) as a brown solid. The data are available in Table 2.
[0393] Route F
[0394] Procedure for the Preparation of Example 13, 4-((S)-1-((R)-2-((4-(difluoromethyl)benzyl)oxy)-3-methylbutyrylamino)ethyl)benzoic acid
[0395]
[0396] Step (i): Under nitrogen atmosphere at 0 ℃, to NaH (~60% in mineral oil) (0.08g, 2.15mmol) suspension in DMF (5mL) add intermediate 1,4-((S)-1-((R)-2-hydroxy-3-methylbutyrylamino)ethyl)methyl benzoate (0.20g, 0.71mmol). The mixture is stirred at the same temperature for 15 minutes, and then 1-(bromomethyl)-4-(difluoromethyl)benzene (0.23g, 1.07mmol) is added. The mixture is stirred at 0 ℃ for 2 hours, and then the mixture is acidified to pH 1 and then distributed between EtOAc and water by adding 1N HCl. The organic matter is separated, and the water layer is further extracted with EtOAc (×2). The combined organics were dried over Na2SO4 and concentrated, and the residue was purified by flash column chromatography (reverse phase, C18) under a gradient of MeCN (0%-72%) in water to provide Example 11, 4-((S)-1-((R)-2-((4-(difluoromethyl)benzyl)oxy)-3-methylbutyrylamino)ethyl)benzoic acid (82 mg, 0.20 mmol, 29% yield) as a white solid. The data are available in Table 2.
[0397] Route G
[0398] Procedure for the Preparation of Example 17, 4-((1S)-1-(2-((3-fluorobenzyl)oxy)-3-methylbutyrylamino)ethyl)benzoic acid, Diastereomer 1 and Example 18, 4-((1S)-1-(2-((3-fluorobenzyl)oxy)-3-methylbutyrylamino)ethyl)benzoic acid, Diastereomer 2
[0399]
[0400] Step (i): 4-((1S)-1-(2-((3-fluorobenzyl)oxy)-3-methylbutyrylamino)ethyl)benzoic acid (110 mg, synthesized according to route E) was purified by chiral preparative HPLC [Chiralpak IG, 21×250 mm, 5 μm, 23 mL / min; gradient [time (min) / solvent B in A (%)]: 0.01 / 8, 40.00 / 8; solvent: solvent A=0.1% TFA and 0.1% diethylamine in hexane; solvent B=methanol:IPA (60:40)] was separated into single diastereomers to provide 4-((1S)-1-(2-((3-fluorobenzyl)oxy)-3-methylbutyrylamino)ethyl)benzoic acid, diastereomer 1 (29 mg, 0.078 mmol) as a white solid and 4-((1S)-1-(2-((3-fluorobenzyl)oxy)-3-methylbutyrylamino)ethyl)benzoic acid, diastereomer 2 (29 mg, 0.078 mmol) as a white solid. The data are available in Table 2.
[0401] Route H
[0402] Procedure for the Preparation of Example 42, (R)-N-((S)-1-(4-(1H-tetrazol-5-yl)phenyl)ethyl)-2-((4-fluorobenzyl)oxy)-3-methylbutanamide
[0403]
[0404] Step (i): Under nitrogen atmosphere at 0 ℃, to NaH (~60% in mineral oil) (45mg, 1.11mmol) suspension in DMF (3mL) add intermediate 4, (R)-N-((S)-1-(4-cyanophenyl)ethyl)-2-hydroxy-3-methylbutanamide (0.25g, 1.01mmol). The mixture is stirred at the same temperature for 15 minutes, then 1-(bromomethyl)-4-fluorobenzene (0.29g, 1.52mmol) is added and the mixture is stirred at room temperature for 2 hours. The mixture is distributed between EtOAc and water and the organic matter is separated. The water layer is further extracted with EtOAc (×2), and the combined organic matter is dried over Na2SO4, then concentrated. The residue was purified by flash column chromatography (reverse phase, C18) under a gradient of MeCN (0%-74%) in water to afford (R)-N-((S)-1-(4-cyanophenyl)ethyl)-2-((4-fluorobenzyl)oxy)-3-methylbutanamide (0.20 g, 0.56 mmol, 56% yield) as a yellow solid. (LC / MS Method E): m / z 355 [M+H] + (ES + ), UV activity at 1.73 min.
[0405] Step (ii): A mixture of (R)-N-((S)-1-(4-cyanophenyl)ethyl)-2-((4-fluorobenzyl)oxy)-3-methylbutanamide (0.10 g, 0.28 mmol), NaN (0.11 g, 1.69 mmol) and NH4Cl (90 mg, 1.69 mmol) in DMF (1 mL) was heated to 80° C. for 7 hours. The mixture was cooled to room temperature and then partitioned between EtOAc and water. The organics were separated and the aqueous layer was further extracted with EtOAc (×2). The combined organics were dried over Na2SO4, concentrated, and the crude material was purified by flash column chromatography (reverse phase, C18) under a gradient of MeCN (0%-45%) in water to afford Example 42, ((R)-N-((S)-1-(4-(1H-tetrazol-5-yl)phenyl)ethyl)-2-((4-fluorobenzyl)oxy)-3-methylbutanamide (0.064 g, 57.06%) as a yellow solid. The data are available in Table 2.
[0406] Route I
[0407] Procedure for the Preparation of Example 45, 4-((S)-1-((R)-2-((3-(hydroxymethyl)benzyl)oxy)-3-methylbutyrylamino)ethyl)benzoic acid
[0408]
[0409] Step (i): Under nitrogen atmosphere at 0 ℃, to NaHH (~60% in mineral oil) (24mg, 0.60mmol) suspension in DMF (2mL) add intermediate 1,4-((S)-1-((R)-2-hydroxy-3-methylbutyrylamino)ethyl)benzoic acid methyl ester (0.15g, 0.54mmol). The mixture is stirred at the same temperature for 10 minutes, and then 3-(bromomethyl)benzaldehyde (0.16g, 0.81mmol) is added. The mixture is heated to room temperature and stirred for 2 hours, and then the mixture is distributed between EtOAc and water. The organic matter is separated, and the water layer is further extracted with EtOAc (×2). The combined organic matter is dried over Na2SO4 and concentrated. The residue was purified by flash column chromatography (reverse phase, C18) under a gradient of MeCN (0%-74%) in water to afford methyl 4-((S)-1-((R)-2-((3-formylbenzyl)oxy)-3-methylbutyrylamino)ethyl)benzoate (0.14 g, 0.35 mmol, 66% yield) as an off-white solid. (LC / MS Method D): m / z 398 [M+H] + (ES + ), UV activity at 2.46 min.
[0410] Step (ii): To a solution of methyl 4-((S)-1-((R)-2-((3-formylbenzyl)oxy)-3-methylbutyrylamino)ethyl)benzoate (0.13 g, 0.33 mmol) in 1,4-dioxane (1 mL) and water (0.5 mL) was added lithium hydroxide monohydrate (70 mg, 1.64 mmol). The mixture was stirred at room temperature for 2 hours, after which it was acidified to pH 1 with 1N HCl and partitioned between EtOAc and water. The organics were separated, the acidic aqueous layer was further extracted with EtOAc (×2) and the combined organics were concentrated to provide 4-((S)-1-((R)-2-((3-formylbenzyl)oxy)-3-methylbutyrylamino)ethyl)benzoic acid (0.13 g, 0.33 mmol, 100% yield) as an off-white solid. (LC / MS method D): m / z 384 [M+H] + (ES + ), UV activity at 2.15 min.
[0411] Step (iii): To a solution of 4-((S)-1-((R)-2-((3-formylbenzyl)oxy)-3-methylbutyrylamino)ethyl)benzoic acid (0.12 g, 0.31 mmol) in MeOH (3 mL) was added NaBH4 (0.12 g, 0.31 mmol) at 0°C. The mixture was stirred at room temperature for 1 hour, after which it was acidified to pH 1 with 1N HCl and partitioned between EtOAc and water. The organics were separated, and the acidic aqueous layer was further extracted with EtOAc. The combined organics were concentrated and the residue was purified by flash column chromatography (reverse phase, C18) under a gradient of MeCN (0%-35%) in water to provide Example 45, 4-((S)-1-((R)-2-((3-(hydroxymethyl)benzyl)oxy)-3-methylbutyrylamino)ethyl)benzoic acid (60 mg, 0.16 mmol, 50% yield) as a white solid. The data are available in Table 2.
[0412] Route J
[0413] Procedure for the Preparation of Example 47, 4-((1S)-1-(3-methyl-2-((4-(oxetan-3-yl)benzyl)oxy)butyrylamino)ethyl)benzoic acid
[0414]
[0415] Step (i): At 0°C under nitrogen atmosphere, intermediate 35, (4-(oxetanes-3-yl)phenyl)methanol (0.30 g, 1.82 mmol) was added to a stirred suspension of NaH (~60% in mineral oil) (0.08 g, 2.01 mmol) in DMF (3 mL), and the reaction mixture was stirred at room temperature for 15 min. Then intermediate 3, methyl 4-((1S)-1-(3-methyl-2-((methylsulfonyl)oxy)butyrylamino)ethyl)benzoate (0.91 g, 2.56 mmol) was added and the reaction mixture was allowed to stir at room temperature for 2 hours. The reaction mixture was quenched with saturated aqueous NH4Cl solution (3 mL), and the reaction mixture was distributed between water (70 mL) and EtOAc (60 mL). The aqueous layer was further extracted with EtOAc (2×25 mL). The organic layers were combined and dried (Na2SO4). The solvent was removed in vacuo and the crude product was purified by reverse phase gradient flash column chromatography (reverse phase, C18 silica) eluting with 0% to 57% ACN in water to afford crude methyl 4-((1S)-1-(3-methyl-2-((4-(oxetan-3-yl)benzyl)oxy)butyrylamino)ethyl)benzoate (0.11 g, 15%) as a yellow sticky solid. (LC / MS Method D): m / z 426 [M+H] + (ES + ), UV activity at 2.17min and 2.21min.
[0416] Step (ii): To a solution of methyl 4-((1S)-1-(3-methyl-2-((4-(oxetan-3-yl)benzyl)oxy)butyrylamino)ethyl)benzoate (0.11 g, 0.27 mmol) in dioxane (1.0 mL) and water (1.0 mL) was added LiOH monohydrate (0.034 g, 0.81 mmol) at room temperature and the reaction mixture was allowed to stir at room temperature for 3 hours. The reaction mixture was then acidified with glacial acetic acid (0.3 mL) to adjust to pH ~ 4 and concentrated in vacuo. The crude product obtained was purified by reverse phase gradient flash column chromatography (reverse phase, C18 silica) eluting with 0% to 35% ACN in water to provide pure Example 47, 4-((1S)-1-(3-methyl-2-((4-(oxetan-3-yl)benzyl)oxy)butyrylamino)ethyl)benzoic acid (0.042 g, 39%) as a white solid. The data are available in Table 2.
[0417] Route K
[0418] Procedure for the Preparation of Example 48, 4-((1S)-1-(3-methyl-2-((3-(oxetan-3-yl)benzyl)oxy)butyrylamino)ethyl)benzoic acid, Diastereomer 1 and Example 49, 4-((1S)-1-(3-methyl-2-((3-(oxetan-3-yl)benzyl)oxy)butyrylamino)ethyl)benzoic acid, Diastereomer 2
[0419]
[0420] Step (i): At room temperature under nitrogen atmosphere, a solution of intermediate 36, (3-(oxetanes-3-yl)phenyl)methanol (0.10g, 0.60mmol) in THF (1mL) was added to a suspension of potassium tert-butoxide (0.20g, 1.82mmol) in THF (2mL) and stirred for 15min. Intermediate 3, 4-((1S)-1-(3-methyl-2-((methylsulfonyl)oxy)butyrylamino)ethyl)methyl benzoate (0.32g, 0.91mol) was added and the reaction mixture was allowed to stir at room temperature for 3 hours. The reaction mixture was distributed between water (30mL) and EtOAc (50mL). The aqueous layer was further extracted with EtOAc (2×30mL). The organic layers were combined and dried (Na2SO4), the solvent was removed in vacuo, and the crude product was purified by reverse phase gradient flash column chromatography (reverse phase, C18 silica) eluting with 0% to 67% ACN in water to afford pure methyl 4-((1S)-1-(3-methyl-2-((3-(oxetan-3-yl)benzyl)oxy)butyrylamino)ethyl)benzoate (0.060 g, 16%) as a colorless sticky solid. (LC / MS Method D): m / z 426 [M+H] + (ES + ), UV activity at 2.15 min.
[0421] Step (ii): LiOH monohydrate (0.030 g, 0.70 mmol) was added to a solution of methyl 4-((1S)-1-(3-methyl-2-((3-(oxetan-3-yl)benzyl)oxy)butyrylamino)ethyl)benzoate (0.060 g, 0.14 mmol) in dioxane (1.0 mL) and water (0.5 mL) at room temperature, and the reaction mixture was allowed to stir at room temperature for 3 hours. The reaction mixture was then acidified with glacial acetic acid (0.3 mL) to adjust to pH ~ 4 and concentrated in vacuo. The crude product obtained was purified by reverse phase gradient flash column chromatography (reverse phase, C18 silica) eluting with 0% to 56% ACN in water to provide pure 4-((1S)-1-(3-methyl-2-((3-(oxetan-3-yl)benzyl)oxy)butyrylamino)ethyl)benzoic acid (0.045 g, 78%) as a colorless sticky solid. (LC / MS Method D): m / z 412 [M+H] + (ES + ), UV activity at 1.87min & 1.89min.
[0422] Diastereoisomer separation: 4-((1S)-1-(3-methyl-2-((3-(oxetan-3-yl)benzyl)oxy)butyrylamino)ethyl)benzoic acid was separated by chiral preparative HPLC [Chiralpak IG SFC, 21×250 mm, 5 μm, 16 mL / min; gradient [time (min) / solvent B in A (%)]: 0.01 / 20, 45.00 / 20; solvent: solvent A = n-heptane; solvent B = methanol:IPA (30:70)] was separated into single diastereomers to provide Example 47, 4-((1S)-1-(3-methyl-2-((3-(oxetan-3-yl)benzyl)oxy)butyrylamino)ethyl)benzoic acid, diastereomer 1, (0.010 g, 22%) as an off-white solid and Example 48, 4-((1S)-1-(3-methyl-2-((3-(oxetan-3-yl)benzyl)oxy)butyrylamino)ethyl)benzoic acid, diastereomer 2, (0.0091 g, 20%) as a white solid. The data are available in Table 2.
[0423] Route L
[0424] Procedure for the Preparation of Example 38, 4-((S)-1-((R)-2-((3-hydroxybenzyl)oxy)-3-methylbutyrylamino)ethyl)benzoic acid
[0425]
[0426] Step (i): K2CO3 (0.08 g, 0.58 mmol) and Pd(PPh3)4 (0.017 g, 0.014 mmol) were added to a solution of 4-((S)-1-((R)-2-((3-allyloxy)benzyl)oxy)-3-methylbutyrylamino)ethyl)-benzoic acid (0.12 g, 0.29 mmol) in dichloromethane (2 mL) and methanol (2 mL) at room temperature. The reaction was then heated to 50°C for 4 hours. The reaction mixture was concentrated in vacuo to give the crude product which was purified by two reverse phase gradient flash column chromatography (reverse phase, C18 silica) eluting with 0% to 56% ACN in 0.1% FA in water to afford pure Example 38, 4-((S)-1-((R)-2-((3-hydroxybenzyl)oxy)-3-methylbutyrylamino)ethyl)-benzoic acid (0.045 g, 40%) as an off-white solid. The data are available in Table 2.
[0427] Route M
[0428] Procedure for the Preparation of Example 51, 4-((1S)-1-((2R)-3-methyl-2-(1-(4-(trifluoromethyl)phenyl)ethoxy)butyrylamino)ethyl)benzoic acid
[0429]
[0430] Step (i): at 0 ℃ under nitrogen atmosphere, intermediate 1,4-((S)-1-((R)-2-hydroxy-3-methylbutyrylamino)ethyl)benzoic acid methyl ester (0.20g, 0.71mmol) is added to the suspension of NaH (~60% in mineral oil) (0.034g, 0.85mmol) in DMF (4mL) stirring, and the reaction mixture is stirred at 0 ℃ for 10min. After this time, intermediate 39, 1-(1-bromoethyl)-4-(trifluoromethyl)benzene (0.27g, 1.07mmol) is added and the reaction mixture is stirred at room temperature for 4 hours. Then the reaction mixture is distributed between saturated aqueous NH4Cl solution (40mL) and EtOAc (30mL). The water layer is further extracted with EtOAc (2×50mL). The organic layers were combined and dried (Na2SO4), the solvent was removed in vacuo, and the crude product was purified by reverse phase gradient flash column chromatography (reverse phase, C18 silica) eluting with 0% to 46% ACN in water to provide a crude product that was further purified by preparative TLC using 70% EtOAc:hexanes to yield pure Example 51, 4-((1S)-1-((2R)-3-methyl-2-(1-(4-(trifluoromethyl)phenyl)ethoxy)butyrylamino)ethyl)benzoic acid (0.020 g, 6.4%) as a brown sticky solid. Data are available in Table 2.
[0431] Route N
[0432] Procedure for the Preparation of Example 53, 4-((S)-1-((R)-3-methyl-2-((4-(trifluoromethyl)benzyl)oxy)butyrylamino)ethyl)-N-(methylsulfonyl)benzamide
[0433]
[0434] Step (i): To a solution of Example 1, 4-[(1S)-1-[[(2R)-3-methyl-2-[[4-(trifluoromethyl)phenyl]methoxy]butanoyl]amino]ethyl]benzoic acid (150 mg, 0.350 mmol), DMAP (129.84 mg, 1.06 mmol) and EDCI (101.86 mg, 0.530 mmol) in DCM (1.5 mL) was added methanesulfonamide (84.24 mg, 0.890 mmol). The mixture was stirred at room temperature for 3 days before being diluted with DCM. The mixture was washed with water and brine, dried (frit) and concentrated. The crude material was purified by reverse phase HPLC (Gilson semi-preparative HPLC system, Gemini-NX, 5 μm, C18, 100×30 mm) eluting with 5%-85% ACN in water with 0.2% 28% ammonia solution to provide Example 53, N-methylsulfonyl-4-[(1S)-1-[[(2R)-3-methyl-2-[[4-(trifluoromethyl)phenyl]methoxy]butanoyl]amino]ethyl]benzamide (99 mg, 56% yield) as a colorless oil. The data are available in Table 2.
[0435] Route O
[0436] Procedure for the Preparation of Example 73, (R)-4-(1-(3-methyl-2-((4-(trifluoromethyl)benzyl)oxy)butyrylamino)cyclobutyl)benzoic acid
[0437]
[0438] Step (i): To an ice-cold solution of intermediate 43, (2R)-N-[1-(4-cyanophenyl)cyclobutyl]-2-hydroxy-3-methyl-butyramide (109 mg, 0.400 mmol) and potassium tert-butoxide (49.4 mg, 0.440 mmol) was added intermediate 31, 4-(trifluoromethyl)benzyl bromide (105 mg, 0.440 mmol), and the reaction mixture was stirred at room temperature for 4 hours. The reaction mixture was partitioned between ethyl acetate and water, after which the organics were separated, washed with brine, dried (frit) and concentrated. The residue was purified by flash column chromatography (normal phase, [5.9×2.0 cm (10 g)], Purification by SNAP KP-Sil-50 μm irregular silica, 30 mL / min, [gradient 0% to 50% ethyl acetate in isohexane]) afforded (R)-N-(1-(4-cyanophenyl)cyclobutyl)-3-methyl-2-((4-(trifluoromethyl)benzyl)oxy)butanamide (109 mg, 63% yield) as a colorless oil. (LC / MS Method B): m / z 431 [M+H]+ (ES + ), UV activity at 1.76 min.
[0439] Step (ii): A suspension of (R)-N-(1-(4-cyanophenyl)cyclobutyl)-3-methyl-2-((4-trifluoromethyl)benzyl)oxy)butyramide (109 mg, 0.250 mmol) in 5M (aqueous) sodium hydroxide (0.8 mL, 4 mmol) and ethanol (0.42 mL) was heated to reflux for 18 hours before concentrating. The crude material was partitioned between ethyl acetate and 1 M HCl, dried (frit) and concentrated. The crude material was purified by reverse phase HPLC under basic conditions (Gilson semi-preparative HPLC system, Gemini-NX, 5 μm, C18, 100×30 mm) eluting with 50%-80% ACN in water with 0.2% of 28% ammonia solution to provide Example 73, (R)-4-(1-(3-methyl-2-((4-(trifluoromethyl)benzyl)oxy)butyrylamino)cyclobutyl)benzoic acid (3 mg, 2.6% yield), which was scraped to give a white solid. The data are available in Table 2.
[0440] Route P
[0441] Procedure used to prepare Example 92, 4-((1S)-1-(2-cyclobutyl-2-((4-(trifluoromethyl)benzyl)oxy)acetylamino)ethyl)benzoic acid; Example 93, 4-((1S)-1-(2-cyclobutyl-2-((4-(trifluoromethyl)benzyl)oxy)acetylamino)ethyl)benzoic acid, Diastereomer 1 and Example 94, 4-((1S)-1-(2-cyclobutyl-2-((4-(trifluoromethyl)benzyl)oxy)acetylamino)ethyl)benzoic acid, Diastereomer 2.
[0442]
[0443] Step (i): 4-(trifluoromethyl)benzyl bromide (182 mg, 0.76 mmol) was added to an ice-cold solution of 2-cyclobutyl-2-hydroxy-acetic acid methyl ester (100 mg, 0.69 mmol) and potassium tert-butoxide (85 mg, 0.76 mmol) in DMF (3.5 mL), and the reaction mixture was heated to room temperature and stirred for 18 hours. The reaction mixture was partitioned between EtOAc and water, after which the organics were separated, washed with brine, dried and concentrated through a hydrophobic frit. The crude material was purified by flash column chromatography (normal phase) [gradient 0%-40% EtOAc in isohexane] to provide 2-cyclobutyl-2-((4-(trifluoromethyl)benzyl)oxy)acetic acid methyl ester (79 mg, 0.26 mmol, 38%) as a colorless oil. LC / MS (Method B): m / z 303 [M+H] + (ES + ), UV activity at 1.79 min.
[0444] Step (ii): lithium hydroxide monohydrate (44 mg, 1.06 mmol) was added to a suspension of 2-cyclobutyl-2-((4-(trifluoromethyl)benzyl)oxy)acetic acid methyl ester (79 mg, 0.26 mmol) in 1,4-dioxane (0.6 mL) and water (0.6 mL). The reaction mixture was stirred at room temperature for 18 hours and then concentrated. The crude material was distributed between 1M HCl (aqueous) and EtOAc, and the organic matter was separated. The water layer was further extracted with EtOAc, and the combined organic matter was dried and concentrated through a hydrophobic frit to provide 2-cyclobutyl-2-((4-(trifluoromethyl)benzyl)oxy)acetic acid (76 mg, 0.26 mmol, quantitative) as a colorless oil. The crude material was used without any further purification. LC / MS (method B): m / z 311 [M+Na] + (ES + ), UV activity at 0.68 min.
[0445] Step (iii): 4-[(1S)-1-aminoethyl] methyl benzoate (51 mg, 0.29 mmol), 2-cyclobutyl-2-((4-(trifluoromethyl)benzyl)oxy)acetic acid (76 mg, 0.26 mmol), EDC (76 mg, 0.40 mmol) and HOBt monohydrate (4 mg, 0.03 mmol) were dissolved in DCM (0.8 mL) and the reaction mixture was stirred at room temperature for 10 minutes. At 0 ° C, triethylamine (0.09 mL, 0.66 mmol) was added dropwise, and the reaction mixture was heated to room temperature and stirred for 18 hours. The reaction mixture was distributed between water and EtOAc, and the organic matter was separated and washed with 1M HCl (aqueous), saturated NaHCO (aqueous) and brine. The organic matter was dried and concentrated through a hydrophobic frit. The crude material was purified by flash column chromatography (normal phase) [gradient 0%-50% EtOAc in isohexane] to afford methyl 4-((1S)-1-(2-cyclobutyl-2-((4-(trifluoromethyl)benzyl)oxy)acetamido)ethyl)benzoate (82 mg, 0.18 mmol, 69%) as a white solid. LC / MS (Method B): m / z 450 [M+H] + (ES + ), UV activity at 1.77 min.
[0446] Step (iv): To a suspension of methyl 4-((1S)-1-(2-cyclobutyl-2-((4-(trifluoromethyl)benzyl)oxy)acetamido)ethyl)benzoate (82 mg, 0.18 mmol) in 1,4-dioxane (0.5 mL) and water (0.5 mL), lithium hydroxide monohydrate (30 mg, 0.73 mmol) was added. The reaction mixture was stirred at room temperature for 18 hours and then concentrated. The crude material was distributed between 1M HCl (aqueous) and EtOAc, and the organic matter was separated. The water layer was further extracted with EtOAc, and the combined organic matter was dried and concentrated via passing through a hydrophobic frit. The crude material was purified by flash column chromatography (normal phase) [gradient 0% to 6% MeOH in DCM (0.1% acetic acid)] to isolate Example 92, racemic 4-((1S)-1-(2-cyclobutyl-2-((4-(trifluoromethyl)benzyl)oxy)acetamido)ethyl)benzoic acid as a white solid. The data are available in Table 2.
[0447] Step (v): Example 92, racemic 4-((1S)-1-(2-cyclobutyl-2-((4-(trifluoromethyl)benzyl)oxy)acetamido)ethyl)benzoic acid was purified by chiral preparative SFC [Phenomenex Lux Amylose-1, 250×21.2 mm, 5 μm] and isocratic conditions CO : EtOH (0.1% NH ) 80:20 were separated into single diastereomers to provide Example 93, 4-((1S)-1-(2-cyclobutyl-2-((4-(trifluoromethyl)benzyl)oxy)acetylamino)ethyl)benzoic acid (19 mg, 0.04 mmol, 46%) as a white solid and Example 94, 4-((1S)-1-(2-cyclobutyl-2-((4-(trifluoromethyl)benzyl)oxy)acetylamino)ethyl)benzoic acid (19 mg, 0.04 mmol, 46%) as a white solid. The data are available in Table 2.
[0448] Route Q
[0449] Procedure for the Preparation of Example 95, 4-(1-(2-cyclobutyl-2-((3-(methylsulfonyl)benzyl)oxy)acetylamino)cyclopropyl)benzoic acid
[0450]
[0451] Step (i): to the intermediate 58 in DMF (3.3mL), 4-(1-(2-cyclobutyl-2-hydroxyacetylamino) cyclopropyl) methyl benzoate (150mg, 0.49mmol) and potassium tert-butoxide (61mg, 0.54mmol) ice-cold solution add 1-(bromomethyl)-3-methylsulfonyl-benzene (135mg, 0.54mmol), and the reaction mixture is heated to room temperature and stirred for 18 hours. Make the reaction mixture distributed between EtOAc and water, and organic matter is separated, washed with salt water, dried and concentrated via passing through hydrophobic frit. The crude material was purified by reverse phase HPLC under basic conditions (Gilson semi-preparative HPLC system, Gemini-NX, 5 μm, C18, 100×30 mm) eluting with 40%-70% ACN in water with 0.2% of 28% ammonia solution to afford methyl 4-(1-(2-cyclobutyl-2-((3-methylsulfonyl)benzyl)oxy)acetamido)cyclopropyl)benzoate (34 mg, 0.07 mmol, 14%) as a white solid. LC / MS (Method B): m / z 472 [M+H] + (ES + ), UV activity at 1.35 min.
[0452] Step (ii): lithium hydroxide monohydrate (12 mg, 0.29 mmol) was added to a suspension of 4-(1-(2-cyclobutyl-2-((3-(methylsulfonyl)benzyl)oxy)acetylamino)cyclopropyl)benzoic acid methyl ester (34 mg, 0.07 mmol) in 1,4-dioxane (0.2 mL) and water (0.2 mL). The reaction mixture was stirred at room temperature for 18 hours and then concentrated. The crude material was distributed between 1M HCl (aqueous) and EtOAc, and the organic matter was separated. The water layer was further extracted with EtOAc, and the combined organic matter was dried and concentrated via passing through a hydrophobic frit. The crude material was purified by flash column chromatography (normal phase) [Gradient: 0-6% MeOH in DCM (0.1% acetic acid)] to provide Example 95, 4-(1-(2-cyclobutyl-2-((3-methylsulfonyl)benzyl)oxy)acetamido)cyclopropyl)benzoic acid (20 mg, 0.04 mmol, 60%) as a white solid. The data are available in Table 2.
[0453] Route R
[0454]
[0136] Procedures for the preparation of Example 99, 4-(1-(2-cyclobutyl-2-((3-(difluoromethoxy)benzyl)oxy)acetamido)cyclopropyl)benzoic acid; Example 100, (S)-4-(1-(2-cyclobutyl-2-((3-(difluoromethoxy)benzyl)oxy)acetamido)cyclopropyl)benzoic acid, and Example 101, (R)-4-(1-(2-cyclobutyl-2-((3-(difluoromethoxy)benzyl)oxy)acetamido)cyclopropyl)benzoic acid.
[0455]
[0456] Step (i): to the intermediate 58 in DMF (3.3mL), 4-(1-(2-cyclobutyl-2-hydroxyacetylamino) cyclopropyl) methyl benzoate (150mg, 0.49mmol) and potassium tert-butoxide (61mg, 0.54mmol) ice-cold solution add 1-(bromomethyl)-3-(difluoromethoxy) benzene (128mg, 0.54mmol), and the reaction mixture is heated to room temperature and stirred for 18 hours. Make the reaction mixture distributed between EtOAc and water, then organic matter is separated, washed with salt water, dried and concentrated via passing through hydrophobic frit. The crude material was purified by flash column chromatography (normal phase) [gradient 0%-60% EtOAc in isohexane] to afford methyl 4-(1-(2-cyclobutyl-2-((3-(difluoromethoxy)benzyl)oxy)acetamido)cyclopropyl)benzoate (130 mg, 0.28 mmol, 57%) as a colorless oil. LC / MS (Method B): m / z 460 [M+H] + (ES + ), UV activity at 1.62 min.
[0457] Step (ii): lithium hydroxide monohydrate (100 mg, 2.40 mmol) was added to a suspension of 4-(1-(2-cyclobutyl-2-((3-(difluoromethoxy)benzyl)oxy)acetylamino)cyclopropyl)benzoic acid methyl ester (276 mg, 0.60 mmol) in 1,4-dioxane (1.5 mL) and water. The reaction mixture was stirred at room temperature for 18 hours and then concentrated. The crude material was distributed between 1M HCl (aqueous) and EtOAc, and the organic matter was separated. The water layer was further extracted with EtOAc, and the combined organic matter was dried and concentrated via passing through a hydrophobic frit. The crude material was purified by reverse phase HPLC under basic conditions (Gilson semi-preparative HPLC system, Gemini-NX, 5 μm, C18, 100×30 mm) eluting with 15%-25% ACN in water with 0.2% 28% ammonia solution to provide Example 99, racemic 4-(1-(2-cyclobutyl-2-((3-(difluoromethoxy)benzyl)oxy)acetamido)cyclopropyl)benzoic acid (146 mg, 0.33 mmol, 54%) as a white solid. The data are available in Table 2.
[0458] Step (iii): Example 99, racemic 4-(1-(2-cyclobutyl-2-((3-(difluoromethoxy)benzyl)oxy)acetamido)cyclopropyl)benzoic acid was separated using chiral preparative SFC [Phenomenex Lux Amylose-1, 250×21.2 mm, 5 μm] and isocratic conditions CO2:IPA 70:30 to provide Example 100, (S)-4-(1-(2-cyclobutyl-2-((3-(difluoromethoxy)benzyl)oxy)acetamido)cyclopropyl)benzoic acid (47 mg, 0.33 mmol, 34%) as a white solid and Example 101, (R)-4-(1-(2-cyclobutyl-2-((3-(difluoromethoxy)benzyl)oxy)acetamido)cyclopropyl)benzoic acid (47 mg, 0.33 mmol, 34%) as a white solid. The data are available in Table 2. Analytical SFC (Method J) of Example 100 (1.99 min) and Example 101 (2.05 min) was used to show that this batch of Example 101 made using Route R matched the batch of Example 101 made using Route S (2.04 min).
[0459] Route S
[0460] Alternative Procedure for the Preparation of Example 101, (R)-4-(1-(2-cyclobutyl-2-((3-(difluoromethoxy)benzyl)oxy)acetamido)cyclopropyl)benzoic acid
[0461]
[0462] Step (i): at 0 ℃, to 2-amino-2-cyclobutylacetic acid (10.0g, 77.5mmol) solution in water (100mL) and aqueous H sO 4 solution (0.5M, 180mL) add sodium nitrite (32g, 465.1mmol), and the reaction mixture is heated to room temperature and stirred for 16 hours. Make the reaction mixture distributed between water and THF. Water layer is further extracted four times with THF. The organic layer dried (Na sO 4 ) and concentrated by merging. The crude residue is washed with EtOAc and the filtrate is concentrated to provide the crude 2-cyclobutyl-2-hydroxyacetic acid (8.0g, 61.5mmol, 79%) as yellow liquid. This material is used in the absence of further purification.
[0463] Step (ii): HATU (20.1 g, 52.8 mmol) was added to a suspension of 2-cyclobutyl-2-hydroxyacetic acid (6.88 g, 52.8 mmol) and methyl 4-(1-aminocyclopropyl)benzoate hydrochloride (8.0 g, 35.2 mmol) in ACN (70 mL) at 0 ° C, and stirring was allowed to continue for 15 min at 0 ° C, followed by addition of DIPEA (18.4 mL, 105.7 mmol). The reaction mixture was heated to room temperature and stirred for 16 hours, then concentrated. The crude residue was purified by reversed phase gradient flash column chromatography (reverse phase, C18 silica), and the product was eluted with 0% to 56% ACN in water to provide methyl 4-(1-(2-cyclobutyl-2-hydroxyacetylamino)cyclopropyl)benzoate (2.9 g, 9.6 mmol, 47%) as a brown solid. LC / MS (Method D): m / z 304 [M+H] + (ES + ), UV activity at 1.51 min.
[0464] Step (iii): to the solution of 4-(1-(2-cyclobutyl-2-hydroxyacetylamino)cyclopropyl)benzoic acid methyl ester (5.0g, 16.5mmol) in DCM (50mL), add (R)-2-methoxy-2-phenylacetic acid (3g, 18.14mmol), N, N '-dicyclohexylcarbodiimide (4.08g, 19.8mmol) and DMAP (0.40g, 3.29mmol). The reaction mixture is stirred at room temperature for 16 hours, then distributed between water and DCM. The water layer is extracted twice with DCM. The organic matter combined is dried (Na2SO4) and concentrated. The crude residue was purified by normal phase gradient flash column chromatography (normal phase, silica) with the product eluting with 0% to 95% diethyl ether in petroleum ether to afford methyl 4-(1-((R)-2-cyclobutyl-2-((R)-2-methoxy-2-phenylacetoxy)acetamido)cyclopropyl)benzoate (2.6 g, 5.76 mmol, 35%) as a white solid and methyl 4-(1-((S)-2-cyclobutyl-2-((R)-2-methoxy-2-phenylacetoxy)acetamido)cyclopropyl)benzoate (1.0 g, 2.22 mmol, 13%) as a white solid. LC / MS (Method I): m / z 453 [M+H] + (ES + ), UV activity at 8.13 min.
[0465] Step (iv): To a solution of methyl 4-(1-((R)-2-cyclobutyl-2-((R)-2-methoxy-2-phenylacetoxy)acetylamino)cyclopropyl)benzoate (2.6 g, 5.76 mmol) in water (5 mL) and MeOH (5 mL) was added KCO (1.19 g, 8.64 mmol), and the resulting solution was stirred at room temperature for 3 hours. The reaction mixture was partitioned between water and EtOAc, and the aqueous layer was further extracted twice with EtOAc. The combined organic layers were dried (NaSO) and concentrated to provide (R)-methyl 4-(1-(2-cyclobutyl-2-hydroxyacetylamino)cyclopropyl)benzoate (1.90 g, 6.27 mmol, quantitative) as an off-white solid. LC / MS (Method D): m / z 304 [M+H] + (ES + ), UV active at 1.52 min. Chiral HPLC (Method K) was used to determine the stereochemical configuration of the R enantiomer (12.06 min) and the S enantiomer (10.35 min) by comparison with the known R enantiomer (12.15 min) synthesized in chiral route T using (R)-2-cyclobutylglycine.
[0466] Step (v): at 0 ℃ under nitrogen atmosphere, (R)-4-(1-(2-cyclobutyl-2-hydroxyacetylamino)cyclopropyl)benzoic acid methyl ester (1.9g, 6.26mmol) is added to the stirred suspension of NaH (~60% in mineral oil, 0.27g, 6.89mmol) in DMF (10mL). The reaction mixture is stirred at 0 ℃ for 30min, then 1-(bromomethyl)-3-(difluoromethoxy)benzene (1.78g, 7.54mmol) is added. The reaction mixture is heated to room temperature and stirred for 1 hour, after which the reaction mixture is distributed between water and ETOAC. The water layer is further extracted twice with EtOAc. The combined organic matter is dried (Na2SO4) and concentrated. The crude residue was purified by reverse phase gradient flash column chromatography (reverse phase, C18 silica) eluting the product with 0% to 56% ACN in water to afford (R)-methyl 4-(1-(2-cyclobutyl-2-((3-(difluoromethoxy)benzyl)oxy)acetamido)cyclopropyl)benzoate (2.1 g, 4.57 mmol, 73%) as an off-white solid. LC / MS (Method D): m / z 460 [M+H] + (ES + ), UV activity at 2.27 min.
[0467] Step (vi): To a solution of (R)-methyl 4-(1-(2-cyclobutyl-2-((3-(difluoromethoxy)benzyl)oxyacetamido)cyclopropyl)benzoate (2.0 g, 4.35 mmol) in dioxane (5 mL) and water (3 mL) was added LiOH monohydrate (532 mg, 12.77 mmol). The reaction mixture was stirred at room temperature for 4 hours, then acidified with glacial acetic acid to reach pH ~4 and concentrated. The crude residue was The product was purified by reverse phase gradient flash column chromatography (reverse phase, C18 silica) eluting with 0% to 58% ACN in water to provide Example 101, (R)-4-(1-(2-cyclobutyl-2-((3-(difluoromethoxy)benzyl)oxy)acetamido)cyclopropyl)benzoic acid (1.29 g, 2.90 mmol, 67%) as a white solid. Chiral HPLC (Method K) 13.57 min. Data are available in Table 2.
[0468] Route T
[0469] Alternative Procedure for the Preparation of Example 101, (R)-4-(1-(2-cyclobutyl-2-((3-(difluoromethoxy)benzyl)oxy)acetamido)cyclopropyl)benzoic acid
[0470]
[0471] A third route for preparing Example 101 is shown in the scheme above using step i - step iv, similar to step i - step ii & step v - step vi shown in Route S. The spectral details were consistent with those given for Example 101 produced in Route S.
[0472] General synthetic procedures for intermediates
[0473] Route 1
[0474] Procedure for the preparation of intermediate 1,4-((S)-1-((R)-2-hydroxy-3-methylbutyrylamino)ethyl)benzoic acid methyl ester
[0475]
[0476] Step (i): To an ice-cold solution of (2R)-2-hydroxy-3-methyl-butyric acid (10.0 g, 84.7 mmol) and (S)-methyl 4-(1-aminoethyl)benzoate (16.7 g, 93.1 mmol) in DMF (170 mL) was added EDC HCl (24.3 g, 127.0 mmol), ethyl (hydroxyimino)cyanoacetate (13.2 g, 93.1 mmol) and triethylamine (29.5 mL, 211.6 mmol). The mixture was stirred at room temperature for 18 hours before being partitioned between EtOAc and water. The organics were separated, washed sequentially with 1M HCl, saturated aqueous NaHCO3 and brine, dried over MgSO4 and concentrated to provide the intermediate methyl 1,4-((S)-1-((R)-2-hydroxy-3-methylbutyrylamino)ethyl)benzoate (12.8 g, 45.9 mmol, 54% yield) as an orange solid. The data are available in Table 3.
[0477] Route 2
[0478] Procedure for the preparation of intermediate 2,4-((1S)-1-(2-hydroxy-3-methylbutyrylamino)ethyl)benzoic acid methyl ester and intermediate 3,4-((1S)-1-(3-methyl-2-((methylsulfonyl)oxy)butyrylamino)ethyl)benzoic acid methyl ester
[0479]
[0480] Step (i): to a solution of (S)-4-(1-aminoethyl) methyl benzoate (6.00 g, 33.5 mmol) and 2-hydroxy-3-methylbutyric acid (4.35 g, 36.8 mmol) in DCM (100 mL), EDC HCl (9.62 g, 50.2 mmol) and HOBt (900 mg, 0.66 mmol) were added. The mixture was stirred at room temperature for 10 minutes, then at 0 ° C, triethylamine (13.5 mL, 100.4 mmol) was added. The mixture was stirred at room temperature for 4 hours, then the mixture was distributed between DCM and saturated aqueous NaHCO 3 . The organic matter was separated, and the aqueous layer was further extracted with DCM (× 2). The combined organics were dried over Na2SO4, concentrated, and the crude material was purified by flash column chromatography (reverse phase, C18) under a gradient of MeCN (0%-26%) in water to afford methyl 4-((1S)-1-(2-hydroxy-3-methylbutyrylamino)ethyl)benzoate (6.50 g, 23.3 mmol, 70% yield) as a white solid. Data are available in Table 3.
[0481] Step (ii): At 0°C, methanesulfonyl chloride (1.8 mL, 24.0 mmol) was added dropwise to a solution of methyl 4-((1S)-1-(2-hydroxy-3-methylbutyrylamino)ethyl)benzoate (6.70 g, 24.0 mmol) and triethylamine (3.52 mL, 26.40 mmol) in DCM (100 mL). The mixture was stirred at room temperature for 2 hours, after which the mixture was distributed between water and DCM. The organic matter was separated, and the aqueous layer was further extracted with DCM. The combined organic matter was washed successively with 1N HCl and then with saturated aqueous NaHCO, dried over NaSO and concentrated to provide methyl 4-((1S)-1-(3-methyl-2-((methylsulfonyl)oxy)butyrylamino)ethyl)benzoate (7.50 g, 21.0 mmol, 88% yield) as a white solid. Data are available in Table 3.
[0482] Route 3
[0483] Procedure for the preparation of Intermediate 4, (R)-N-((S)-1-(4-cyanophenyl)ethyl)-2-hydroxy-3-methylbutanamide
[0484]
[0485] Step (i): To a solution of (S)-(1-(4-cyanophenyl)ethyl)tert-butyl carbamate (1.00 g, 4.06 mmol) in 1,4-dioxane (10 mL) was added 4N HCl in 1,4-dioxane (10 mL). The mixture was stirred at room temperature for 16 hours, after which the mixture was concentrated under reduced pressure. The crude material was ground by 10% EtOAc in EtO to provide (S)-4-(1-aminoethyl)benzonitrile hydrochloride (0.57 g, 3.13 mmol, 77% yield) as a yellow solid. (LC / MS Method D): m / z 147 [M+H-HCl] + (ES + ), UV activity at 0.75 min.
[0486] Step (ii): To a solution of (R)-2-hydroxy-3-methylbutanoic acid (0.39 g, 3.29 mmol) in MeCN (6 mL) was added (S)-4-(1-aminoethyl)benzonitrile hydrochloride (0.50 g, 2.74 mmol), followed by HATU (1.56 g, 4.11 mmol). The mixture was stirred at room temperature for 30 minutes, after which it was cooled to 0 ° C and N, N-diisopropylethylamine (1.47 mL, 8.23 mmol) was added. The mixture was stirred at room temperature for 4 hours, after which the mixture was partitioned between EtOAc and water. The organics were separated, and the aqueous layer was further extracted with EtOAc (×2). The combined organics were dried over Na2SO4, concentrated, and the crude material was purified by flash column chromatography (reverse phase, C18) under a gradient of MeCN (0%-73%) in water to provide intermediate 4, (R)-N-((S)-1-(4-cyanophenyl)ethyl)-2-hydroxy-3-methylbutanamide (0.55 g, 2.24 mmol, 82% yield) as a sticky brown solid. Data are available in Table 3.
[0487] Route 4
[0488] Procedure for the preparation of Intermediate 5, (R)-methyl 4-(1-(2-hydroxy-3-methylbutyrylamino)cyclopropyl)benzoate
[0489]
[0490] Step (i): To (2R)-2-hydroxy-3-methyl-butyric acid (200 mg, 1.69 mmol) in DMF (8.5 mL) was added DIPEA (0.9 mL, 5.08 mmol) and HATU (775 mg, 2.03 mmol), followed by methyl 4-(1-aminocyclopropyl)benzoate (356 mg, 1.86 mmol). The reaction mixture was stirred at room temperature for 18 hours and then partitioned between EtOAc and water. The organics were separated, washed with brine, dried (phase separator) and concentrated in vacuo. The crude material was purified by flash column chromatography (normal phase) [gradient 0%-75% EtOAc in isohexane] to provide intermediate 5, methyl (R)-4-(1-(2-hydroxy-3-methylbutyrylamino)cyclopropyl)benzoate (212 mg, 0.73 mmol, 43%) as a dark orange solid. Data are available in Table 3.
[0491] Route 5
[0492] Procedure for the preparation of Intermediate 22, 4-(bromomethyl)-1-(difluoromethyl)-2-fluorobenzene
[0493]
[0494] Step (i): at 0 ℃ under nitrogen atmosphere, to 4-(difluoromethyl)-3-fluorobenzaldehyde (0.50g, 2.87mmol) in MeOH (3mL) solution NaBH4(0.21g, 5.74mmol).The mixture is stirred at room temperature for 1 hour, and then the mixture is distributed between EtOAc and water.Organism is separated, and water layer is further extracted with EtOAc (×2).The combined organic matter is dried over Na2SO4 and concentrated to provide (4-(difluoromethyl)-3-fluorophenyl)methanol (0.47g, 2.67mmol, 93% yield) as a colorless liquid. 1 H NMR (400MHz, DMSO) δ4.55 (d, J=5.8Hz, 2H), 5.45 (t, J=5.8Hz, 1H), 6.97-7.35 (m, 3H), 7.50-7.62 (m, 1H).
[0495] Step (ii): triphenylphosphine (0.55 g, 2.13 mmol) was added to a solution of (4-(difluoromethyl)-3-fluorophenyl)methanol (0.25 g, 1.42 mmol) in DCM (3 mL). The mixture was cooled to 0 ° C. and tetrabromomethane (0.71 g, 2.13 mmol) was added. The mixture was stirred at room temperature for 1 hour, after which the mixture was distributed between EtOAc and water. The organic matter was separated, and the aqueous layer was further extracted with EtOAc (× 2). The combined organic matter was dried over Na2SO4, concentrated, and the crude material was purified by flash column chromatography (normal phase, silica) under a gradient of EtOAc (0% to 18%) in hexane to provide intermediate 22, 4-(bromomethyl)-1-(difluoromethyl)-2-fluorobenzene (0.19 g, 0.80 mmol, 56% yield) as a colorless liquid. Data are available in Table 3.
[0496] Route 6
[0497] Procedure for the preparation of Intermediate 27, 2-(bromomethyl)-5-(difluoromethyl)pyridine
[0498]
[0499] Step (i): NaBH4 (0.14 g, 3.82 mmol) was added to a solution of 5-(difluoromethyl)picolinaldehyde (0.30 g, 1.91 mmol) in MeOH (3 mL) at 0°C under a nitrogen atmosphere. The mixture was stirred at room temperature for 1 hour, after which the mixture was partitioned between EtOAc and water. The organics were separated, and the aqueous layer was further extracted with EtOAc (×2). The combined organics were dried over Na2SO4 and concentrated to provide (5-(difluoromethyl)pyridin-2-yl)methanol (0.30 g, 1.88 mmol, 99% yield) as a colorless liquid. (LC / MS Method D): m / z 160 [M+H] + (ES + ), UV activity at 0.95 min.
[0500] Step (ii): At 0 ° C, to a solution of phosphorus tribromide (0.36 mL, 3.77 mmol) in DCM (3 mL), (5-(difluoromethyl)pyridin-2-yl)methanol (0.30 g, 1.88 mmol) was added. The mixture was stirred at room temperature for 1 hour, after which the mixture was partitioned between EtOAc and saturated aqueous NaHCO. The organics were separated, and the aqueous layer was further extracted with EtOAc (×2). The combined organics were dried over NaSO, concentrated, and purified by flash column chromatography (normal phase, silica) under a gradient of EtOAc (0% to 40%) in hexane to provide intermediate 27, 2-(bromomethyl)-5-(difluoromethyl)pyridine (0.17 g, 0.77 mmol, 41% yield) as a yellow liquid. Data are available in Table 3.
[0501] Route 7
[0502] Procedure for the preparation of intermediate 32, 1-(bromomethyl)-3-(ethylsulfonyl)benzene
[0503]
[0504] Step (i): Potassium disulfite (3.19g, 18.3mmol), tetrabutylammonium bromide (2.58g, 8.01mmol), sodium formate (1.03g, 15.3mmol), palladium acetate (II) (85mg, 0.38mmol), triphenylphosphine (0.28g, 1.06mmol) and 1,10-phenanthroline (0.178g, 0.99mmol) in DMSO (28mL) are purged with nitrogen at room temperature for 15min. Methyl 3-iodobenzoate (2.00g, 7.60mmol) is added, and the mixture is heated to 100°C for 30 minutes under microwave irradiation. The mixture is cooled, ethyl iodide (1.00mL, 12.4mmol) is added and the mixture is stirred at room temperature for 20 minutes. The mixture is distributed between EtOAc and water, organic matter is separated, and the water layer is further extracted with EtOAc (×2). The combined organics were dried over Na2SO4, concentrated, and the residue was purified by flash column chromatography (reverse phase, C18) under a gradient of MeCN (0%-36%) in water to afford methyl 3-(ethylsulfonyl)benzoate (1.00 g, 4.39 mmol, 57% yield) as a light yellow viscous liquid. (LC / MS Method H): m / z 229 [M+H] + (ES + ), UV activity at 6.98 min.
[0505] Step (ii): LiAlH4 (1M in THF, 6.50 mL) was added dropwise to a solution of methyl 3-(ethylsulfonyl)benzoate (1.00 g, 4.39 mmol) in THF (10 mL) at -78 °C under a nitrogen atmosphere. The mixture was stirred at the same temperature for 2 hours, after which the mixture was partitioned between saturated aqueous NH4Cl and EtOAc. The organics were separated, and the aqueous layer was further extracted with EtOAc (×2). The combined organics were dried over Na2SO4, concentrated under reduced pressure, and the residue was purified by flash column chromatography (reverse phase, C18) under a gradient of MeCN (0%-35%) in water to provide (3-(ethylsulfonyl)phenyl)methanol (0.50 g, 2.49 mmol, 57% yield) as a pale yellow viscous liquid. (LC / MS Method H): m / z 218 [M+H] + (ES + ), UV activity at 5.56 min.
[0506] Step (iii): At 0°C, to a solution of phosphorus tribromide (0.48 mL, 4.99 mmol) in DCM (5 mL), (3-(ethylsulfonyl)phenyl)methanol (0.50 g, 2.49 mmol) was added. The mixture was stirred at room temperature for 1 hour, after which the mixture was partitioned between DCM and saturated aqueous NaHCO. The organics were separated, and the aqueous layer was further extracted with DCM (×2). The combined organics were dried over NaSO, concentrated, and the residue was purified by flash column chromatography (normal phase, silica) under a gradient of EtOAc (0% to 43%) in hexane to provide intermediate 32, 1-(bromomethyl)-3-(ethylsulfonyl)benzene (0.24 g, 0.91 mmol, 38% yield) as a colorless viscous liquid. Data are available in Table 3.
[0507] Route 8
[0508] Procedure for the preparation of Intermediate 33, methyl 4-((S)-1-((R)-2-hydroxy-3-methylbutyrylamino)ethyl)-2-methylbenzoate
[0509]
[0510] Step (i): (S)-4-(1-aminoethyl)-2-methylbenzoic acid methyl ester hydrochloride (0.15g, 0.65mmol) and (R)-2-hydroxy-3-methylbutyric acid (0.085g, 0.72mmol) are suspended in ACN (2mL) at room temperature. Then at 0°C, HATU (0.37g, 0.98mmol) is added and stirring is allowed to continue for 15min. After this time, at 0°C, N, N-diisopropylethylamine (0.34mL, 1.96mmol) is added and stirring is allowed to continue for 2 hours at room temperature. The reaction mixture is distributed between water (15mL) and EtOAc (20mL). The water layer is further extracted with EtOAc (2×15mL). The organic layers are combined and dried (Na2SO4). The solvent was removed in vacuo and the crude product was purified by reverse phase gradient flash column chromatography (reverse phase, C18 silica) eluting with 0% to 60% ACN in water to afford pure intermediate 33, methyl 4-((S)-1-((R)-2-hydroxy-3-methylbutyrylamino)ethyl)-2-methylbenzoate (0.16 g, 85%) as a viscous oily yellow liquid.
[0511] The data are available in Table 3.
[0512] Route 9
[0513] Procedure for the preparation of intermediate 36, 3-(oxetan-3-yl)phenyl)methanol
[0514]
[0515] Step (i): (3-(methoxycarbonyl)phenyl)boronic acid (2.0 g, 11.07 mmol), 3-iodooxetane (4.07 g, 22.1 mmol) and KCO (4.58 g, 33.2 mmol) were dissolved in dry 1,4-dioxane (10 mL). Argon was purged through the mixture at room temperature for 20 min, then Ni(NO) hexahydrate (0.161 g, 0.55 mmol) and 4,4′-di-tert-butyl-2,2′-bipyridine (0.14 g, 0.55 mmol) were added, and the reaction mixture was heated to 80° C. for 4 hours. The reaction mixture was then distributed between water (250 mL) and EtOAc (250 mL). The aqueous layer was further extracted with EtOAc (2×150 mL). The organic layers were combined and dried (Na2SO4), the solvent was removed in vacuo, and the crude product was purified by reverse phase gradient flash column chromatography (reverse phase, C18 silica) eluting the product with 0% to 46% ACN in water to afford pure methyl 3-(oxetan-3-yl)benzoate (0.58 g, 27%) as a colorless liquid. 1 H NMR (400MHz, DMSO-d6) δ3.86 (s, 3H), 4.33 (tt, J=8.3, 6.6Hz, 1H), 4.60 (dd, J=6.6, 6.0Hz, 2H), 4.97 (dd, J=8.3, 6 .0Hz, 2H), 7.54 (t, J=7.7Hz, 1H), 7.71 (dt, J=7.7, 1.3Hz, 1H), 7.87 (dt, J=7.7, 1.4Hz, 1H), 7.98 (t, J=1.8Hz, 1H).
[0516] Step (ii): under nitrogen atmosphere at -78 ℃, by LiAlH (2M in THF) (2.26mL, 4.52mmol) dropwise added to 3- (oxetanes -3- bases) methyl benzoate (0.58g, 3.01mmol) in dry THF (8mL) solution, and allow reaction mixture to stir at -78 ℃ for 1 hour.Saturated aqueous NH4Cl solution (3mL) quenching of reaction mixture, then distributed between water (150mL) and EtOAc (50mL), and aqueous layer is further extracted with EtOAc (2 × 70mL).Organic layers are merged and dried (Na2SO4) and solvent is removed in vacuo to provide crude (3- (oxetanes -3- bases) phenyl) methanol (0.43g, 87%) as colorless liquid.Data are available in Table 3.
[0517] Route 10
[0518] Procedure for the preparation of intermediate 42, 7-(chloromethyl)imidazo[1,2-a]pyridine
[0519]
[0520] Step (i): under nitrogen atmosphere at 0 ℃, thionyl chloride (0.2mL, 3.03mmol) is added to imidazo [1,2-a] pyridine -7- base methanol (0.30g, 2.02mmol) in CHCl (4mL) solution, and then allow stirring at room temperature for 1 hour. Remove solvent in vacuum, and the crude material is purified and dried by grinding with diethyl ether (3 × 10mL), to provide pure intermediate 42 as brown solid, 7- (chloromethyl) imidazo [1,2-a] pyridine (0.31g, 92%). Data are available in Table 3.
[0521] Route 11
[0522] Procedure for the preparation of Intermediate 48, 1-(bromomethyl)-3-(cyclopropylsulfonyl)benzene
[0523]
[0524] Step (i): potassium disulfite (3.19g, 14.3mmol), tetrabutylammonium bromide (2.58g, 8.01mmol), sodium formate (1.04g, 15.3mmol), palladium acetate (II) (0.085g, 0.38mmol), triphenylphosphine (0.28g, 1.06mmol) and 1,10-phenanthroline (0.178g, 0.99mmol) are suspended in DMSO (12mL), and nitrogen is purged at room temperature for 20min. After this time, 3-iodobenzoic acid methyl esters (2.00g, 7.63mmol) are added, and the reaction mixture is heated to 100 ℃ and continues 30min in microwave. Then at room temperature, 1-chloro-3-iodopropane (1.00mL, 9.31mmol) is added, and the reaction mixture is allowed to stir at room temperature for 16 hours. The reaction mixture was then distributed between water (250mL) and EtOAc (250mL). The aqueous layer was further extracted with EtOAc (2 × 150mL), and the combined organic layers were combined and dried (Na2SO4). The solvent was removed in a vacuum, and the crude product was purified by reversed-phase gradient flash column chromatography (reverse phase, C18 silica), and the product was eluted with 0% to 57% ACN in water to provide crude 3-((3-chloropropyl) sulfonyl) methyl benzoate (0.55g, 26.00%) as a brown viscous liquid. (LC / MS method H): m / z 277[M+H] + (ES + ), UV activity at 8.00 min.
[0525] Step (ii): Under nitrogen atmosphere at room temperature, methyl 3-((3-chloropropyl)sulfonyl)benzoate (0.70g, 2.53mmol) was dissolved in THF (6mL). The reaction mixture was then cooled to 0°C, potassium tert-butoxide (0.31g, 2.78mmol) was added, and the reaction mixture was allowed to stir at room temperature for 2.5 hours. The reaction mixture was then distributed between water (150mL) and EtOAc (200mL). The aqueous layer was acidified with 1N aqueous HCl (2.0mL) to adjust the pH to ~3, and the aqueous layer was further extracted with EtOAc (2×150mL). The organic layers were combined and dried (Na2SO4) and the solvent was removed in vacuo to provide crude 3-(cyclopropyl)sulfonyl)benzoic acid (0.52g, 85%) as a yellow solid. (LC / MS method H): m / z 227 [M+H] + (ES + ), UV activity at 6.86 min.
[0526] Step (iii): Under nitrogen atmosphere at room temperature, 3-(cyclopropylsulfonyl)benzoic acid (0.50g, 2.21mmol) is dissolved in dry THF (5mL).Then the reaction mixture is cooled to 0°C, and at 0°C, BH3.DMS (0.52mL, 5.53mmol) is added dropwise, and then the reaction mixture is allowed to stir at room temperature for 16 hours.Then the reaction mixture is diluted with MeOH (10mL).The solvent is removed in vacuo, and the crude product is purified by reversed-phase gradient flash column chromatography (reverse phase, C18 silica), and the product is eluted with 0% to 68% ACN in water to provide (3-(cyclopropylsulfonyl)phenyl)methanol (0.17g, 36%) as a yellow viscous liquid. (LC / MS method H): m / z 213[M+H] + (ES + ), UV activity at 5.96 min.
[0527] Step (iv): at 0 ℃, phosphorus tribromide (0.14mL, 1.44mmol) is dissolved in dichloromethane (1mL), and at 0 ℃, a solution of (3-(cyclopropylsulfonyl)phenyl)methanol (0.153g, 0.72mmol) in DCM (1mL) is dropwise treated, and the reaction mixture is then allowed to stir at room temperature for 0.5 hours. The reaction mixture is then alkalized to pH~8 with saturated NaHCO solution (10mL), and distributed between water (40mL) and DCM (40mL). The aqueous layer is further extracted with DCM (2×20mL), and the organic layers are combined and dried (Na 2 SO 4 ). The solvent is removed in vacuo to provide crude 1-(bromomethyl)-3-(cyclopropylsulfonyl)benzene (0.09g, 46%) as a colorless liquid. Data are available in Table 3.
[0528] Route 12
[0529] Procedure for the preparation of Intermediate 50, (R)-N-(1-(4-cyanophenyl)cyclopropyl)-2-hydroxy-3-methylbutanamide
[0530]
[0531] Step (i): 1-(4-chlorophenyl)cyclopropane-1-carboxylic acid (55.0 g, 0.281 mole) and triethylamine (77.75 mL, 0.561 mole) were dissolved in toluene (250 mL) at room temperature. After this, diphenylphosphoryl azide (66.51 mL, 0.309 mole) and tert-butyl alcohol (133.13 mL, 1.403 mole) were added, and the reaction mixture was stirred at 80 ° C for 16 h. The reaction mixture was distributed between water (1000 mL) and DCM (600 mL). The water layer was further extracted with DCM (2 × 400 mL). The organic layers were combined and dried (Na2SO4). The solvent was removed in vacuo and the crude product was purified by gradient flash column chromatography (normal phase, silica) eluting with 0% to 10% EtOAc in hexanes to afford tert-butyl (1-(4-chlorophenyl)cyclopropyl)carbamate (60.0 g, 80%) as an off-white solid. (LC / MS Method D): m / z 168.07 (ES+, M-100) at 2.18 min.
[0532] Step (ii): tert-butyl (1-(4-chlorophenyl) cyclopropyl) carbamate (20.00g, 74.87 mmoles) and zinc cyanide (13.18g, 112.31 mmoles) are suspended in dioxane (45mL), and nitrogen is purged for 30min at room temperature. After this, bis(tri-tert-butylphosphine) palladium (0) (3.82g, 7.48 mmoles) are added at room temperature, and the reaction mixture is stirred for 3h at 80 ℃. The reaction mixture is distributed between water (1000mL) and EtOAc (700mL), and the water layer is further extracted with EtOAc (2×300mL). The organic layers are merged and dried (Na2SO4). The solvent was removed in vacuo and the crude product was purified by gradient flash column chromatography (normal phase, silica) eluting with 0% to 15% EtOAc in hexanes to provide pure tert-butyl (1-(4-cyanophenyl)cyclopropyl)carbamate (11.4 g, 58.98%) as a brown solid. It should be noted that the reaction was carried out in 2 separate batches at 10 g scale. (LC / MS Method D): m / z 159 (ES-100) at 1.85 min.
[0533] Step (iii): under nitrogen atmosphere, tert-butyl (1-(4-cyanophenyl)cyclopropyl)carbamate (3.00g, 11.62 mmoles) was dissolved in dioxane (10mL). At room temperature, 4N HCl in dioxane (30mL) was added thereto, and stirring at room temperature continued for 16h. The solvent was removed in a vacuum, and the crude material was purified by grinding with diethyl ether (20mL) to provide 4-(1-aminocyclopropyl)benzonitrile hydrochloride (2.10g, 93%) as a white solid. (LC / MS method H): m / z 159 (ES+), at 0.73min.
[0534] Step (iv): (R)-2-hydroxy-3-methylbutanoic acid (1.53 g, 12.98 mmol) was dissolved in ACN (20 mL), and 4-(1-aminocyclopropyl)benzonitrile hydrochloride (2.10 g, 10.82 mmol) was added to the reaction mixture at room temperature. After this, HATU (6.17 g, 16.23 mmol) was added, and the reaction mixture was allowed to stir at room temperature for 30 min. After this, N,N-diisopropylethylamine (5.64 mL, 32.46 mmol) was added at 0°C and allowed to stir at room temperature for 1 h. The reaction mixture was concentrated in vacuo to give the crude product which was purified by reverse phase gradient flash column chromatography (reverse phase, C18 silica) eluting with 0% to 61% ACN in water to provide (R)-N-(1-(4-cyanophenyl)cyclopropyl)-2-hydroxy-3-methylbutanamide, intermediate 50 (1.80 g, 64.%) as a brown solid. Data are available in Table 3.
[0535] Route 13
[0536] Procedure for the preparation of intermediate 58, methyl 4-(1-(2-cyclobutyl-2-hydroxyacetamido)cyclopropyl)benzoate.
[0537]
[0538] Step (i): 4-(1-aminocyclopropyl) methyl benzoate (1.45g, 7.61mmol), 2-cyclobutyl-2-hydroxy-acetic acid (900mg, 6.92mmol), EDC (2.0g, 10.37mmol) and HOBt monohydrate (93mg, 0.69mmol) are dissolved in DCM (21.0mL), and the reaction mixture is stirred at room temperature for 10 minutes afterwards. At 0 ℃, triethylamine (2.4mL, 17.29mmol) is added dropwise, and the reaction mixture is stirred at room temperature for 18 hours. The reaction mixture is distributed between water and EtOAc, and organic matter is separated, with 1M HCl (aqueous), saturated NaHCO (aqueous) and salt water washing. The organics were separated, dried via passing through a hydrophobic frit and concentrated to provide intermediate 58, methyl 4-(1-(2-cyclobutyl-2-hydroxyacetamido)cyclopropyl)benzoate (1.5 g, 4.85 mmol, 70%) as a light brown solid. This material was used without any further purification. The data are available in Table 3.
[0539]
[0540]
[0541]
[0542]
[0543]
[0544]
[0545]
[0546]
[0547]
[0548]
[0549]
[0550]
[0551]
[0552]
[0553]
[0554]
[0555]
[0556]
[0557]
[0558]
[0559]
[0560]
[0561]
[0562]
[0563] Biological activity
[0564] Cloning of HEK293 cells, baculovirus production, large-scale infection and membrane preparation: Human prostaglandin E2 receptor 4 (EP4) was cloned into the pBacMam expression vector (GeneScript, UK). Transposition of EP4 DNA was performed using Invitrogen's Bac-to-Bac baculovirus expression system. P0 baculovirus was produced by transfecting SF9 cells with bacmid DNA using Cellfectin II transfection reagent (ThermoFisher Scientific, UK, catalog number 10362-100). After P0 production, P1 virus was then produced and prepared for large-scale infection and membrane preparation. HEK293 cells were grown in DMEM+Glutamax supplemented with 10% heat-inactivated fetal bovine serum (FBS). 500cm in 5% v / v EP4 Bacman 3The cells were infected with an inoculation density of 3.5 million cells / mL in a flask. Expression was performed at 37°C under 5% CO2 for 36 hours. Cells were removed using PBS and a cell scraper. Cell culture was centrifuged at 4°C for 10 minutes at 2500RPM. The supernatant was then poured out and the precipitate was stored at -80°C. The precipitate was thawed and resuspended in 15mL of homogenizing buffer (20mM HEPES, 10mM EDTA, pH 7.4). Homogenization was then continued for 10 seconds in a mechanical homogenizer (VMR). The membrane was centrifuged at 40,000g in a centrifuge tube at 4°C for 15 minutes. The supernatant was poured out and resuspended in 15mL of homogenizing buffer. Homogenization lasted for 20 seconds. The membrane was centrifuged at 4°C for 45 minutes at 40,000g. The membrane was resuspended in 3 mL of storage buffer (20 mM HEPES, 0.1 mM EDTA, pH 7.4) and mixed thoroughly. The resulting membrane was then stored at -80°C.
[0565] cAMP Gs functional assay; cAMP production upon EP4 receptor activation was determined using the Homogenous Time Resolved Fluorescence (HTRF) cAMP Kinetic-2 assay (Cisbio, France). HEK293 cells were transfected with 0.5% EP4 Bacman virus for 36 hours, then cells were dissociated and frozen at 150°C.
[0566] On the day of testing, increasing concentrations of test compounds along with positive control (1 μM ONO-AE3-208) and negative control (DMSO (Sigma-Aldrich, UK)) were added to ProxiPlate-384 Plus, white 384-shallow well microplates (PerkinElmer, USA) using an ECHO dispenser.
[0567] The cells were thawed in a water bath and resuspended in DMEM supplemented with 10% FBS, then centrifuged at 1200 RPM for 5 minutes to form a pellet. The pellet was resuspended in assay buffer (DMEM + 0.5 mM IBMX (Tocris, Abingdon, UK, catalog number 2845)) to 1×10 6 cells / mL. A cell suspension with a final assay concentration of 5000 cells / well was added to the pre-assigned assay plate using a multidrop. The plate was then incubated at 37°C in 5% CO2 for 30 minutes. After incubation, EC 80The PGE2 (EP4 agonist) of concentration (7nM) is added in this plate. In parallel, PGE2 dose-response curve is assigned to independent plate.Then the assay buffer is assigned on the top.Before reading plate on PheraStar fluorescence plate reader (BMG LabTech, Germany), determine that cAMP produces according to the instructions of manufacturers.
[0568] pIC 50 The modified Cheng Prussoff equation was used to convert the function to pKb value, where K d = agonist EC 50 And L hot =agonist challenge concentration;
[0569]
[0570] Table 4 - Human EP4 fpK b value
[0571]
Claims
1. A compound of formula (1): or a salt thereof, wherein: A is selected from the group consisting of: X is an optionally substituted phenyl ring, an optionally substituted pyridyl ring or an optionally substituted imidazopyridine ring system; R 1 and R 2 is independently H or C optionally substituted by one or more fluorine atoms 1-3 an alkyl group; or R 1 and R 2 are connected to form a 3-6 membered carbocyclic ring, wherein the 3-6 membered carbocyclic ring is optionally substituted with one or more fluorine atoms; R 3 It is H, C 1-3 Alkyl or F; R 4 Is H or C 1-3 alkyl; R 8 It is C 1-3 Alkyl or C 3-6 Cycloalkyl ring; R 10 and R 11 Both are methyl, or R 10 and R 11 are connected to form a cyclobutyl ring; and wherein (i) The compound is a compound of formula (2) or formula (2i): or a salt thereof, wherein: Q, W and T are CH or N; Z and Y are C or N; Where one or none of Q, W, T, Y and Z is N, if Y is N, then R 5 does not exist, and if Z is N, then R 6 does not exist; R 5 and R 6 Independently selected from H, halogen, CN, OH, SF5, C 1-6 Alkyl, C 3-6 Cycloalkyl, C 1-6 Alkoxy, OR 7 、SO2R 7 , CH2OH and CH2OMe, wherein the alkyl group, cycloalkyl group and alkoxy group are optionally substituted by one or more fluorine atoms, and any one atom in the alkyl group or cycloalkyl group can be optionally replaced by a heteroatom selected from O, S and N; or R 5 and R 6 are connected to form a 5-membered or 6-membered carbocyclic or heterocyclic ring, wherein the 5-membered or 6-membered carbocyclic or heterocyclic ring is optionally substituted with one or more fluorine atoms; And R 7 is C optionally substituted by one or more fluorine atoms 1-6 An alkyl group or a C 3-6 a cycloalkyl group; or (ii) X is 2. The compound according to claim 1, which is a compound of formula (3) or formula (3i): or a salt thereof.
3. The compound or salt thereof according to any one of claims 1 to 2, wherein R 1 and R 2 Both are methyl, R 1 and R 2 Both are H, R 1 and R 2 are connected to form a cyclopropyl ring, or R 1 is methyl and R 2 It's H.
4. The compound or salt thereof according to claim 3, wherein R 1 is a methyl group, and R 2 It's H.
5. The compound according to claim 1, which is a compound of formula (4) or formula (4i): or a salt thereof.
6. The compound according to claim 1, which is a compound of formula (5) or formula (5i): or a salt thereof.
7. The compound or salt thereof according to any one of claims 2 and 4 to 6, wherein W, Q and T are CH, and Z and Y are C. 8 . The compound according to claim 3 , or a salt thereof, wherein W, Q and T are CH, and Z and Y are C.
9. The compound according to claim 1, which is a compound of formula (6) or formula (6i): or a salt thereof.
10. The compound or salt thereof according to any one of claims 1 to 2, 4 to 6 and 8 to 9, wherein A is CO2H, CONHSO2Me or a tetrazole ring.
11. The compound or salt thereof according to claim 3, wherein A is CO2H, CONHSO2Me or a tetrazole ring.
12. The compound or salt thereof according to claim 7, wherein A is CO2H, CONHSO2Me or a tetrazole ring.
13. The compound or salt thereof according to claim 10, wherein A is CO2H.
14. The compound or salt thereof according to claim 11 or 12, wherein A is CO2H.
15. A compound or a salt thereof according to any one of claims 1 to 2, 4 to 6, 8 to 9 and 11 to 13, wherein R 3 It is H or methyl.
16. The compound or salt thereof according to claim 3, wherein R 3 It is H or methyl.
17. The compound or salt thereof according to claim 7, wherein R 3 It is H or methyl.
18. The compound or salt thereof according to claim 10, wherein R 3 It is H or methyl.
19. The compound or salt thereof according to claim 14, wherein R 3 It is H or methyl.
20. The compound or salt thereof according to claim 15, wherein R 3 It's H.
21. A compound or a salt thereof according to any one of claims 16 to 19, wherein R 3 It's H.
22. A compound or a salt thereof according to any one of claims 1 to 2, 4 to 6, 8 to 9, 11 to 13 and 16 to 20, wherein R 4 It is H or methyl.
23. The compound or salt thereof according to claim 3, wherein R 4 It is H or methyl.
24. The compound or salt thereof according to claim 7, wherein R 4 It is H or methyl.
25. The compound or salt thereof according to claim 10, wherein R 4 It is H or methyl.
26. The compound or salt thereof according to claim 14, wherein R 4 It is H or methyl.
27. The compound or salt thereof according to claim 15, wherein R 4 It is H or methyl.
28. The compound or salt thereof according to claim 21, wherein R 4 It is H or methyl.
29. The compound or salt thereof according to claim 22, wherein R 4 It's H.
30. A compound or salt thereof according to any one of claims 23 to 28, wherein R 4 It's H.
31. A compound or salt thereof according to any one of claims 1 to 2, 4 to 6, 8 to 9, 11 to 13, 16 to 20 and 23 to 29, wherein R 5 and R 6 Independently selected from H, Cl, F, CN, OH, SO2Me, SO2Et, SO2-cyclopropyl, SF5, CF3, CF2H, OMe, OCF3, OCF2H, CH2OH, CH2OMe, cyclopropyl and oxetanyl.
32. The compound or salt thereof according to claim 3, wherein R 5 and R 6 Independently selected from H, Cl, F, CN, OH, SO2Me, SO2Et, SO2-cyclopropyl, SF5, CF3, CF2H, OMe, OCF3, OCF2H, CH2OH, CH2OMe, cyclopropyl and oxetanyl.
33. The compound or salt thereof according to claim 7, wherein R 5 and R 6 Independently selected from H, Cl, F, CN, OH, SO2Me, SO2Et, SO2-cyclopropyl, SF5, CF3, CF2H, OMe, OCF3, OCF2H, CH2OH, CH2OMe, cyclopropyl and oxetanyl.
34. The compound or salt thereof according to claim 10, wherein R 5 and R 6 Independently selected from H, Cl, F, CN, OH, SO2Me, SO2Et, SO2-cyclopropyl, SF5, CF3, CF2H, OMe, OCF3, OCF2H, CH2OH, CH2OMe, cyclopropyl and oxetanyl.
35. The compound or salt thereof according to claim 14, wherein R 5 and R 6 Independently selected from H, Cl, F, CN, OH, SO2Me, SO2Et, SO2-cyclopropyl, SF5, CF3, CF2H, OMe, OCF3, OCF2H, CH2OH, CH2OMe, cyclopropyl and oxetanyl.
36. The compound or salt thereof according to claim 15, wherein R 5 and R 6 Independently selected from H, Cl, F, CN, OH, SO2Me, SO2Et, SO2-cyclopropyl, SF5, CF3, CF2H, OMe, OCF3, OCF2H, CH2OH, CH2OMe, cyclopropyl and oxetanyl.
37. The compound or salt thereof according to claim 21, wherein R 5 and R 6 Independently selected from H, Cl, F, CN, OH, SO2Me, SO2Et, SO2-cyclopropyl, SF5, CF3, CF2H, OMe, OCF3, OCF2H, CH2OH, CH2OMe, cyclopropyl and oxetanyl.
38. The compound or salt thereof according to claim 22, wherein R 5 and R 6 Independently selected from H, Cl, F, CN, OH, SO2Me, SO2Et, SO2-cyclopropyl, SF5, CF3, CF2H, OMe, OCF3, OCF2H, CH2OH, CH2OMe, cyclopropyl and oxetanyl.
39. The compound or salt thereof according to claim 30, wherein R 5 and R 6 Independently selected from H, Cl, F, CN, OH, SO2Me, SO2Et, SO2-cyclopropyl, SF5, CF3, CF2H, OMe, OCF3, OCF2H, CH2OH, CH2OMe, cyclopropyl and oxetanyl.
40. A compound or salt thereof according to any one of claims 1 to 2, 4 to 6, 8 to 9, 11 to 13, 16 to 20, 23 to 29 and 32 to 39, wherein R 5 It's H.
41. The compound or salt thereof according to claim 3, wherein R 5 It's H.
42. The compound or salt thereof according to claim 7, wherein R 5 It's H.
43. The compound or salt thereof according to claim 10, wherein R 5 It's H.
44. The compound or salt thereof according to claim 14, wherein R 5 It's H.
45. The compound or salt thereof according to claim 15, wherein R 5 It's H.
46. The compound or salt thereof according to claim 21, wherein R 5 It's H.
47. The compound or salt thereof according to claim 22, wherein R 5 It's H.
48. The compound or salt thereof according to claim 30, wherein R 5 It's H.
49. The compound or salt thereof according to claim 31, wherein R 5 It's H.
50. The compound or salt thereof according to claim 40, wherein R 6 It is CF3 or F.
51. A compound or salt thereof according to any one of claims 41 to 49, wherein R 6 It is CF3 or F.
52. A compound or salt thereof according to any one of claims 1 to 2, 4 to 6, 8 to 9, 11 to 13, 16 to 20 and 23 to 29, wherein R 5 and R 6 are connected to form a fused imidazole ring or a fused dioxolane ring optionally substituted with one or two fluorine atoms.
53. The compound or salt thereof according to claim 3, wherein R 5 and R 6 are connected to form a fused imidazole ring or a fused dioxolane ring optionally substituted with one or two fluorine atoms.
54. The compound or salt thereof according to claim 7, wherein R 5 and R 6 are connected to form a fused imidazole ring or a fused dioxolane ring optionally substituted with one or two fluorine atoms.
55. The compound or salt thereof according to claim 10, wherein R 5 and R 6 are connected to form a fused imidazole ring or a fused dioxolane ring optionally substituted with one or two fluorine atoms.
56. The compound or salt thereof according to claim 14, wherein R 5 and R 6 are connected to form a fused imidazole ring or a fused dioxolane ring optionally substituted with one or two fluorine atoms.
57. The compound or salt thereof according to claim 15, wherein R 5 and R 6 are connected to form a fused imidazole ring or a fused dioxolane ring optionally substituted with one or two fluorine atoms.
58. The compound or salt thereof according to claim 21, wherein R 5 and R 6 are connected to form a fused imidazole ring or a fused dioxolane ring optionally substituted with one or two fluorine atoms.
59. The compound or salt thereof according to claim 22, wherein R 5 and R 6 are connected to form a fused imidazole ring or a fused dioxolane ring optionally substituted with one or two fluorine atoms.
60. The compound or salt thereof according to claim 30, wherein R 5 and R 6 are connected to form a fused imidazole ring or a fused dioxolane ring optionally substituted with one or two fluorine atoms.
61. The compound of claim 1, selected from the group consisting of: or a salt thereof.
62. The compound according to claim 1, which is: or a salt thereof.
63. The compound according to claim 1, which is: or a salt thereof.
64. The compound according to claim 1, which is: or a salt thereof.
65. The compound according to claim 1, which is: or a salt thereof.
66. The compound according to claim 1, which is: or a salt thereof.
67. The compound according to claim 1, which is: or a salt thereof.
68. The compound according to claim 1, which is: or a salt thereof.
69. The compound according to claim 1, which is: or a salt thereof.
70. The compound according to claim 1, which is: or a salt thereof.
71. A compound or salt thereof according to any one of claims 1 to 2, 4 to 6, 8 to 9, 11 to 13, 16 to 20, 23 to 29, 32 to 39, 41 to 50 and 53 to 70 having EP4 receptor antagonist activity.
72. The compound or salt thereof according to claim 3, having EP4 receptor antagonist activity.
73. The compound or salt thereof according to claim 7, having EP4 receptor antagonist activity. The compound or salt thereof according to claim 10, having EP4 receptor antagonist activity. The compound or salt thereof according to claim 14, having EP4 receptor antagonist activity.
76. The compound or salt thereof according to claim 15, having EP4 receptor antagonist activity.
77. The compound or salt thereof according to claim 21, having EP4 receptor antagonist activity.
78. The compound or salt thereof according to claim 22, having EP4 receptor antagonist activity.
79. The compound or salt thereof according to claim 30, having EP4 receptor antagonist activity.
80. The compound or salt thereof according to claim 31, having EP4 receptor antagonist activity. The compound or salt thereof according to claim 40, having EP4 receptor antagonist activity.
82. The compound or salt thereof according to claim 51, having EP4 receptor antagonist activity.
83. The compound or salt thereof according to claim 52, having EP4 receptor antagonist activity.
84. A pharmaceutical composition comprising a compound as defined in any one of claims 1 to 83 or a salt thereof and a pharmaceutically acceptable excipient.
85. Use of a compound or salt thereof according to any one of claims 1 to 83 or a pharmaceutical composition according to claim 84 in the preparation of a medicament for use as an EP4 receptor antagonist.
86. Use of a compound or salt thereof according to any one of claims 1 to 83 or a pharmaceutical composition according to claim 84 in the preparation of a medicament for treating EP4 receptor-mediated cancer.
87. The use according to claim 86, wherein the EP4 receptor-mediated cancer is an epithelial cancer.
88. The use according to claim 87, wherein the EP4 receptor mediated cancer is selected from the GBD neoplasms category of colon and rectum, lip and oral cavity, nasopharynx, other pharynx, gallbladder and bile duct, pancreas, non-melanoma skin, ovary, testis, kidney, bladder, thyroid, mesothelioma, esophagus, stomach, liver, larynx, trachea, bronchi and lung, breast, cervix, uterus and prostate.
89. The use of a compound or salt thereof according to any one of claims 1 to 83 in the preparation of a medicament for treating or preventing EP4 receptor-mediated cancer, wherein the compound or salt thereof is used in combination with radiotherapy and / or chemotherapy and / or immunotherapy and / or other oncology modulators.
Citation Information
Patent Citations
N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors
CN101952244A
Prostaglandin analogues_as EP4 receptor agonists
WO2003008377A1
Novel compounds
WO2009056582A1
Antagonists of prostaglandin d2 receptors
WO2009108720A2
Phenoxyethoxy compounds
WO2014126746A1
